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Musculoskeletal injuries are some of the most prevalent injuries in both civilian 
and military populations and their infections can be difficult to treat, often resulting in 
multiple surgeries and increased costs.  In both previous and recent military operations, 
extremity injuries have been the most common battlefield injuries and many involve 
complex, open fractures.   These extremity injuries are especially susceptible to multiple 
pathogenic, and sometimes drug resistant, bacteria and fungi.  Fungal infections have 
recently become increasingly problematic in both military and civilian populations and 
have significantly higher amputation rates than those from bacterial infections. Many of 
these bacterial and fungal strains adhere to tissue and implanted orthopaedic hardware 
within wounds, forming biofilms.  These problematic, often polymicrobial, infections 
threaten the health of the patient, but the risk also exists of spreading within hospitals to 
become prominent resistant infections.  Local antimicrobial delivery releases high levels 
of antimicrobials directly to injured wound tissue, overcoming sub-bactericidal or sub-
fungicidal antimicrobial levels present in the avascular wound zones.  This research will 
determine the ability of modified chitosan sponges, buffered with sodium acetate or 
blended with polyethylene glycol (PEG), to act as short term adjunctive therapies to 
initial surgical treatment for delivering both antibiotics and/or antifungals for early 
abatement of infection.  The objective of this work was to evaluate both types of 
modified sponges for in vitro and in vivo material characteristics and device functionality. 
In vitro analysis demonstrated both the buffered and PEG modified chitosan sponges 
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exhibited increased degradation and functional cytocompatibility.  The chitosan/PEG 
sponges were able to be loaded with hydrophobic antifungals and the sponges released in 
vitro biologically active concentrations, alone or in combination with the antibiotic 
vancomycin.  Both types of modified sponges exhibited good biocompatibility and slight, 
but not complete, degradation in an in vivo rat intramuscular degradation and 
biocompatibility model.  In an in vivo bacteria biofilm infection prevention mouse model, 
vancomycin loaded chitosan/PEG sponges also cleared more bacteria than the 
unmodified chitosan sponges. These experimental results led to the conclusion that with 
additional research and in vivo studies, the buffered and PEG blended chitosan sponge 
local delivery systems exhibit potential for use as adjunctive bacterial or fungal infection 
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Musculoskeletal trauma, which is an injury to bone and/or muscle tissue, is one of 
the most prevalent types of injuries in the United States.
1
  More than three out of five of 
the unintentional injuries occurring annually in the U.S. are musculoskeletal injuries.
1
 In 
2004, approximately 57.2 million musculoskeletal injuries occurred in the U.S. and 
20,000 of the injured patients died.
1
   The economic cost of these injuries is high due to 
medical (hospitalization, post operative care, therapy, etc.)  costs and salary loss; out of 
the musculoskeletal injuries that occurred in 2004, 1.04 million people were hospitalized 
for an average of 4.7 days, resulting in total estimated hospital costs of $26.65 billion and 
$25,000 per patient.
1
   
Infection associated with these musculoskeletal related injuries also has a 
significant impact on patient morbidity and mortality and can be a devastating 
complication.
2
  Infection and osteomyelitis, a bone infection caused by bacteria or a 
fungus, are especially troublesome in open fractures, which are caused by high energy 
trauma and typically result in both skeletal and soft tissue injury.  The infection rates of 
orthopaedic surgery (total hip arthroplasty) have been reported as 0.8-1.2% while the 
reported infection rates of closed and open fractures are 3.6-8.1% and 17.5-21.2%, 
respectively.
3
 Based on injuries through May 2003, the rate of infection was reported to 
be 26.5% in soldiers with battlefield complex trauma.
4
  During the Vietnam War, 
infectious complications occurred in 3.9% of casualties and septic shock was determined 
to be a leading cause of mortality.
5
   
2 
 
In the Iraq and Afghanistan wars (Operation Iraqi and Enduring Freedom), 
extremity injuries were the most common combat injuries. These extremity injuries are 
especially susceptible to multiple pathogenic, and sometimes drug resistant bacteria or 
fungi, such as methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas 
aeruginosa, Acinetobacter baumannii, Escherichia coli, Aspergillus spp, or Candida 
albicans (C. albicans).
6,7
  In addition to the presence of multidrug resistant bacteria or 
fungi, the presence of necrotic tissue, debris, and fixation devices or implants creates a 
favorable environment for the development of biofilms and corresponding infection.
8
 
According to an estimate by the CDC, approximately 65% of bacterial infections are 
associated with biofilms.
9
  Biofilms are adherent (sessile) bacterial populations of single 
or mixed colonies with protective mechanisms that enable them to communicate between 
themselves and resist antibiotic and antimicrobial agents.
8,10
 In biofilms, the metabolic 
activity of the bacteria is reduced, resulting in less susceptibility to antimicrobials and an 
increased minimal inhibitory concentration (MIC).
10
  Researchers have found the MIC 
for nonadherent P. aeruginosa to be 1 µg/ml tobramycin, but adherent P. aeruginosa in 
biofilms on urinary catheters remained viable after 12 hours of exposure to tobramycin at 
levels as high as 1,000 µg/ml.
8,11
  Systemic antibiotics cannot reach such a high 
concentration at a localized site without toxicity, thereby becoming ineffective against the 
biofilms.
10
   
Invasive fungal infections have become recently troublesome for both military 
and civilian populations, with high mortality rates and high healthcare costs.
2,12,13
  The 
British Military has recently reported higher rates of fungal wound infections in 
casualties from the Helmand Province in Afghanistan.
14
  In a 2011 Trauma Infectious 
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Disease Outcome Study (TIDOS),  it was determined that 36 cases of invasive fungal 
infections (IFI) were found in Operation Enduring Freedom soldiers with blast injuries in 
Afghanistan from June 2009 to December 2010, and 78% of the wounded warriors with 
IFI required lower extremity amputations.
15
  An outbreak of cutaneous mucormycosis 
was also recently reported in victims from the 2011 tornado in Joplin, Missouri.
16
  
Apophysomyces trapeziformis was identified in all 13 infected patients and 10 patients 
required admission to intensive care, but 5 of the infected patients died.
16,17
  While 
invasive fungal infections can be rare in patients without risk factors, higher incidences 
have been found in transplant patients, African Americans, and babies younger than one 
year old.
18,19
  Invasive Candida infection is the third most common cause of hospital-
acquired bloodstream infections and is five times more prevalent in children than 
invasive Aspergillus infection.
19,20
   
Effective wound management often provides faster and more comfortable wound 
healing, which increases patients’ quality of life.  The common steps utilized in wound 
management with orthopaedic injuries and surgical sites are debridement, irrigation, 
dressings, fixation, closure, and systemic antibiotic therapy.
21
  All of these steps are 
utilized by surgeons in order to prevent further damage to the tissues, amputation, or even 
death.  Because systemic antibiotics cannot be administered at very high concentrations 
to fight localized bacteria, local antimicrobial delivery can be an effective route for 
treating wounds and minimizing bacterial infections, when used as an adjunctive therapy 
to systemic dosing.
22
  In addition to issues with antibiotic resistance, toxicity issues can 
arise with systemic drug delivery because drugs are delivered to the entire body.
22
 Local 
antibiotic or antifungal delivery releases high levels of antibiotics directly to injured 
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wound tissue, overcoming sub-bactericidal antibiotic levels present in the avascular 
wound zones.
22,10,23
   
Several materials are currently being utilized as local antibiotic delivery systems, 
but many of these materials have disadvantages, including the need for a removal 
surgery, the inability to load antibiotics directly in the operating room, and limited time 
of delivery.  Polymethylmethacrylate (PMMA) bone cement is one of the most common 
materials used as a local antibiotic carrier for musculoskeletal infection prevention or 
treatment.
24
 While bone cement has shown to reduce infection in severe open fractures, 
some major disadvantages of the material are the need for surgical removal, possible 
biofilm formation, and the development of antibiotic resistant bacteria.
10,25
  Calcium 
sulfate is another commonly used local antibiotic delivery material and is a 
biocompatible, biodegradable material with osteoconductive properties.
26,27
  Although 
calcium sulfate exhibits an antibiotic bolus release followed by extended drug release 
from several hours to weeks, wounds treated with calcium sulfate can develop sterile 
draining sinuses that mimic infected draining sinuses and antibiotic choices and dosages 
can be limited.
26-29
  The collagen sponge is also a degradable drug delivery system, but 
despite the degradable nature and high local antibiotic release of these sponges, the high 
initial level of antibiotics has been reported to generate toxic antibiotic serum levels and 
potential immunogenic responses to the collagen sources can be another problem.
10,30
 
While antibiotics have been studied extensively in local delivery, antifungals have 
not been successfully locally delivered from as many degradable delivery systems 
because of their hydrophobicity for loading and distribution.    The hydrophobic 
antifungal, amphotericin B, has also been incorporated into a few local delivery systems, 
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including poly(methyl methacrylate) bone cement, a hydroxyapatite and chitosan 
composite, a Pluronic® based copolymer gel, and dextran hydrogels.
31-35
 A drawback to 
these developed local antifungal delivery systems is that most are pre-loaded with 
antifungal and are not easily customized by the clinician.  There is a clear need for a 
degradable local delivery system alternative, such as a chitosan device, that can be loaded 
with multiple antimicrobials, including antibiotics and antifungals, at the point of care to 
provide clinicians with a viable adjunctive therapy to systemic antibiotic and antifungal 
delivery.   
Chitosan, a positively charged linear polysaccharide composed of β-(1-4)-2-
amino-2-D-glucosamine (deacetylated) and β-(1-4)-2-acetamido-2-D-glucosamine 
(acetylated) units, has been studied extensively in bioadhesion, drug delivery and tissue 
engineering research and demonstrates promising properties for such biomedical 
applications.
36-40
 Chitosan is produced by deacetylation of the naturally occurring chitin 
from crustacean shells, which is the second most abundant naturally occurring 
polymer.
40,41
  Advantages of chitosan include low cost, biodegradability, high 




 Chitin and chitosan have different degrees of deacetylation (DDA); chitin 
typically has DDA of less than 50% and chitosan has a DDA greater than 50%. 
38
 The 
degree of deacetylation of chitosan affects degradation; as DDA increases, chitosan 
becomes more resistant to degradation.
41
 While in the human body, chitosan is degraded 
by lysozyme, lipasases, chitosanases, and N-acetyl-o-glucosamindase.
43
  Lysozyme 
degrades chitosan through cleavage of glycosidic bonds and has also shown to quickly 
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degrade chitosan in vitro.
44
  Chitosan’s degradation products, glucosamines and 
saccharides, do not elicit chronic foreign body reactions because the human body 
gradually absorbs them.
45
   
When used as a drug delivery system, chitosan effectively carries antibiotics and 
exhibits biodegradation and predictable elution rates.
46
  However, wide variations in in 
vivo degradation of chitosan have been reported; Ma et al. found chitosan scaffolds to 
exhibit minimal degradation after subcutaneous implantation, but Noel and researchers 
reported rapid degradation of chitosan after use as a wound dressing.
47,48
 Previous 
research conducted at the University of Memphis has yielded a topical, porous, 
degradable chitosan sponge that provides an adaptable antibiotic delivery system in 
which tailored dosing and degradation can be achieved.
48,49
 This system can be loaded 
with antibiotics immediately prior to use, allowing for clinician selected antibiotic 
loading, as well as combination loading.
48,49
  However, in order to load hydrophobic 
antifungals into the chitosan sponges, the sponges must be modified, possibly with other 
polymers that have previously shown antifungal solubility.  
The water soluble polymer, polyethylene glycol (PEG) has been found to function  
as a solvent system for a hydrophobic fatty acid, cis-2-decenoic acid, allowing for point 
of care loading of the fatty acid into the chitosan sponges.
50
  Polyethylene glycol exhibits 
protein resistance, which is the resistance of protein accumulation on surfaces, low 
toxicity and immunogenicity; when added to chitosan films, PEG also enhanced protein 
adsorption, cell adhesion, growth, and proliferation.
51
  In addition to films, PEG has been 
used to modify chitosan fibers and hydrogels.
51-54
  Modification of chitosan with PEG can 





 Polyethyelene glycol has also been utilized as a solvent system, either as liposomes or 
nanoparticles, for amphotericin B in systemic delivery.
55-58
  
For the modified chitosan sponges investigated in this body of work, sodium 
acetate buffered and PEG blended chitosan sponges were fabricated and evaluated for in 
vitro material properties and functionality as degradable, biocompatible, local antibiotic 
and/or antifungal delivery systems. The modified chitosan sponges were also investigated 
in vivo to confirm biocompatibility, degradation, and infection prevention.   
Hypothesis 
Chitosan sponges, modified with either a buffer or polyethylene glycol (PEG) will 
form a degradable local delivery system, capable of point of care loading of multiple 
antibiotics and/or hydrophobic antifungals, for use as adjunctive therapy to reduce 










EFFECTS OF SODIUM ACETATE BUFFER ON CHITOSAN SPONGE 
PROPERTIES AND IN VIVO DEGRADATION IN A RAT INTRAMUSCULAR 
MODEL 
Introduction 
Musculoskeletal injuries are some of the most prevalent injuries in both civilian 
and military populations and their infections can be difficult to treat, often resulting in 
multiple surgeries, as well as increased patient morbidity, treatment time, and costs.
1
 In 
military operations, extremity injuries are the most frequent and many involve complex, 
open fractures where bone is exposed to environmental contamination.
2
 Extremity 
injuries are especially susceptible to multiple pathogenic, and sometimes multidrug 
resistant bacteria, such as methicillin resistant Staphylococcus aureus (MRSA), 
Pseudomonas aeruginosa, Acinetobacter baumannii, and Escherichia coli.
3,4
 Up to 25% 
of open fractures develop osteomyelitis, bone infection caused by bacteria or fungus, and 




The current standard of care for extremity wounds includes debridement and 
irrigation of the affected area, as well as fracture stabilization, with serial debridement 
and irrigation steps to follow.
1
 Systemic antibiotics are the current standard method of 
prophylaxis and treatment for infections. Due to the avascular nature of traumatic wound 
sites, delivery of inhibitory concentrations of antibiotics to affected tissue through the 
bloodstream requires high dosing which carries risks ranging from allergic reaction to 
ototoxicity or kidney failure.
2-4
 Local antibiotic delivery, used as an adjunctive therapy to 
systemic dosing, can overcome the issues of sub-bactericidal antibiotic concentrations in 
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the avascular zones of wound sites by providing high levels of antibiotics directly to the 
injured tissues.  
Two of the most commonly used local antibiotic delivery systems in clinical 
practice include antibiotic-loaded polymethylmethacrylate (PMMA) and calcium sulfate 
(CaSO4). Antibiotic loaded PMMA beads provide a predictable release of antibiotic for 
several weeks and reduce the infection rate in severe open fractures, but disadvantages 
include the possibility for surgical removal and long term, sub-inhibitory antibiotic 
concentrations which may encourage antibiotic resistant bacteria strains and/or biofilm 
formation on the implant’s surface.
5-10
 CaSO4 is a degradable material with characteristic, 
high initial antibiotic burst-release in the local wound site, elevated wound drainage, and 
limited antibiotic choices and dosages.
11-14
  
Porous chitosan sponges have been previously developed for rapid local drug 
delivery as an adjunctive therapy during extremity wound debridement and irrigation.
15,16
 
These biocompatible sponges can be loaded at the point of care with physician selected 
antibiotics and then release a high local dose of antibiotic to reduce bacterial levels.
15,16
 
However, one problem is that these sponges do not degrade quickly and can persist in the 
wound, after the sponges have delivered the antibiotic. This delayed degradation is a 
problem because remaining chitosan may act as a nidus for secondary infection. 
One approach to increase chitosan degradation is to decrease crystallinity of the 
chitosan polymer.
24 
Crystallization of the chitosan sponges occurs during sodium 
hydroxide (NaOH) washes, used in the neutralization process. Using different solutions 
for residual acid removal without inducing crystallization could help to increase sponge 
degradation. In this investigation, sodium acetate buffers were used after a NaOH wash 
10 
 
of the chitosan sponges and were compared to neutral sponges with NaOH washes only. 
We hypothesized in vitro and in vivo analysis would reveal that modification of sponges 
using the buffering step in fabrication would increase sponge degradation while not 
affecting biocompatibility, compared to neutral chitosan sponges. The first aim of this 
study was to evaluate whether the buffering procedure affected in vitro degradation and 
biocompatibility, as well as thermal, crystalline, spectroscopic, and morphologic 
properties. We then evaluated the in vivo degradation and biocompatibility of the 
chitosan sponges in a rat dorsal muscle pouch model through both quantitative and 
qualitative histological assessment of the implant sites. 
Materials and Methods 
Fabrication. Chitosan sponges were manufactured using previously described double 
lyophilization methods.
15,17,18
 Chitopharm S chitosan was purchased from Chitinor AS 
(Tromsoe, Norway) having a 82.5 ± 1.7 degree of deacetylation (DDA), 251 ± 17 kDa 
weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity index. All 
acids and buffer solutions were obtained from Fisher Scientific (Pittsburg, PA) First, the 
chitosan was dissolved at 1% (w/v) in a 1% (v/v) blended acid solvent (3:1 ratio of lactic 
to acetic acid). The dissolved chitosan solution was cast (250 mL) in an 11×20 cm 
container, frozen at -20°C, and lyophilized in a Labconco (Kansas City, MO) FreeZone 
2.5 Liter Benchtop Freeze Dry System. The dehydrated, acidic chitosan sponges were 
then either neutralized in NaOH or neutralized in NaOH and soaked in one of two 
different acetate buffer treatments to create neutralized or buffered sponges, respectively. 
For the NaOH neutralization treatment, the sponges were rinsed in 250 mL of 0.6 M 
NaOH for approximately seven minutes, washed with copious amounts of ultrapure water 
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until a neutral pH was reached, and then re-frozen at -20°C and re-lyophilized. Based on 
prior work and preliminary screening using multiple variations of acetate buffer pH, 
concentration, and hydration times, the buffered sponges were fabricated by gently 
compressing the hydrated sponge and then soaking the sponge in approximately 500 mL 
of a 0.25 M acetate buffer at either 4.6 or 5.6 pH. After 30 minutes of hydration in the 
buffer solution, excess buffer solution was removed and the buffered sponge was re-
frozen at -20°C and re-lyophilized. After the second lyophilization the neutral, 4.6 pH 
buffered and 5.6 pH buffered chitosan sponges were stored in a desiccator cabinet until 
subsequent analyses.  
In Vitro Degradation. Degradation of neutralized, 4.6 pH, and 5.6 pH buffered chitosan 
sponges was determined based on mass loss using a protocol previously reported.
18,19
 
Briefly, triplicate samples of each sponge formulation were trimmed to similar sizes and 
weighed on a Mettler Toledo (Columbus, OH) XS205 Dual Range scale to establish an 
initial weight. Samples were placed in a 125 mL Nalgene (Rochester, NY) container and 
hydrated with 35 mL of 1 mg/mL 2× crystallized chicken egg white lysozyme and 
penicillin (100 units/mL), streptomycin (100 mg/mL), amphotericin B (0.25 µg/mL), 
both from MP Biomedicals (Solon, OH), in 1× phosphate buffered saline (PBS). 
Degradation samples were placed on a rocking shaker in an incubator at 37°C and the 
degradation solution was exchanged every 24 hours over 10 days. At each 24 hour 
interval, three replicate chitosan sponge samples from each sponge variation were 
removed from the degradation solution and rinsed in ultrapure water. Sponge samples 
were then placed in a vacuum oven at 60°C for two days until dry and were weighed for a 
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 Percent remaining      
Sponge weight at   days
Initial dry sponge weight 




The gentle, vacuum drying process eliminated the option of utilizing that individual 
samples a second time, and therefore separate samples were analyzed for each replicate 
and time point.  
Molecular Weight. Molecular weight was determined by gel permeation 
chromatography (GPC), using a TOSOH Bioscience (King of Prussia, PA) TSKgel 
G5000PWxl column at 30°C, coupled with a Wyatt (Santa Barbara, CA) DAWN 
HELEOS II multi-angle light scattering detector and Varian Prostar 450 refractive index 
detector. Chitosan samples were dissolved at 1 mg/mL in the mobile phase solution of 
0.15 M acetic acid and 0.1 M sodium acetate at pH 5. An injection volume of 50 µL and 
a specific refractive index increment (dn/dc) for chitosan of 0.163 mL/g were used.
20
  
Crystallinity. X-ray diffraction (XRD) was used to characterize the crystal structure of 
the raw chitosan material, as well as neutral, 4.6 pH, and 5.6 pH buffered chitosan 
sponges. XRD patterns were determined using multiple scans from a Bruker AXS 
(Madison, WI) Advanced D8 X-ray diffractometer with Kα Cu radiation source at 4  kV 
and 4  mA over a 2θ range from 5° to 4 ° with a step size of  . 5° and a time/step of  .2 
seconds.  
Thermal Analysis. A Netzsch (Selb, Germany) 200 PC differential scanning calorimeter 
(DSC) was used to evaluate the thermal properties of the three chitosan sponge 
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formulations and chitosan powder (n = 3). Samples were scanned from 40 to 400°C at 
20°C/min in order to assess variations in endothermic and exothermic peak temperatures. 
Spectral Analysis. In order to evaluate sponge differences, chitosan sponge sample 
functional group chemistries were compared (n = 3) using attenuated total reflectance 
Fourier transform infrared spectrometry (ATR-FTIR) with a ThermoScientific (Waltham, 
MA) Nicolet iS10 FTIR spectrometer with a diamond ATR crystal. Absorbance spectra 
were acquired using 64 scans with a resolution of 4 cm
-1
 and processed using the Thermo 
Scientific OMNIC
TM
 Software Suite. 
Morphology. Surface morphology of the three chitosan sponge formulations (n = 3) was 
assessed using a FEI/Philips XL30 Environmental Scanning Electron Microscope at 
15kV and samples sputter-coated with 30 nm of Au/Pd. Images were visually inspected 
for differences between sponge groups such as surface texture and porosity. 
Direct Contact Biocompatibility. A protocol modified from ASTM F813- 7 “Standard 
Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices” 
was followed in order to assess the direct contact biocompatibility between the chitosan 
sponge variations and normal human dermal fibroblasts (NHDF) purchased from Lonza 
(Walkersville, MD). NHDF cells (passages 4 through 6) were seeded at 6×10
4
 cells/mL 
and allowed proliferate to confluence on BD Falcon (Franklin Lake, NJ) 12-well 
polystyrene tissue culture plates in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/mL), 
streptomycin (100 mg/mL),amphotericin B (0.25 µg/mL), all purchased from Fisher 
Scientific, under standard cell culture conditions (37°C and 5% CO2 atmosphere).  Cell 
culture medium was aspirated and refreshed with 1 mL of fresh medium before a single 8 
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mm diameter test specimen (n = 5) of either a neutralized chitosan sponge, 4.6 pH 
buffered chitosan sponge, 5.6 pH buffered chitosan sponge or a polyurethane sponge 
(control) was gently placed in a well in direct contact with the cell monolayer. Cultures 
were incubated for either one or three days before biocompatibility was assessed with the 
Cell Titer-Glo® Luminescent Cell Viability assay (Promega, Madison, WI).The 
luminescent signal, which corresponded to the amount of adenosine triphosphate and the 
number of viable cells through a standard dilution of known concentrations of cells, was 
recorded at 590 nm using a BioTek (Winooski, VT) FLx-800 Fluorescence Microplate 
Reader.  
In vivo Degradation. A total of 23, three month old male Sprague-Dawley rats (average 
weight of 398 g) were utilized for this study. This pre-clinical study was approved by 
institutional review boards at the University of Memphis (IACUC protocol #0720) and 
the Army Medical Research and Material Command (Protocol DM 090455.02) and 
followed guidelines set forth by both organizations. Rats were anesthetized with 2% 
isoflurane in an environmental chamber and given a sub-cutaneous injection of carprofen 
in the rat flank. The rat was prepared for sterile surgery with anesthesia maintained using 
4 to 5% isoflurane. Two 1.5 cm incisions were made through the skin on each side of the 
midline (4 incisions total). In each incision, a 1.25 cm pouch was created in the latissimus 
dorsi muscle. One disc shaped implant, 9.5 mm in diameter and approximately 5 mm 
thick, was implanted bilaterally in each muscle pouch. Test groups included gamma 
irradiation sterilized (25.0 to 40.0 kGy dosage) neutralized chitosan sponge, 4.6 pH 
buffered chitosan sponge, 5.6 pH buffered chitosan sponge and an absorbable gelatin 
sponge (Gelfoam®, Pfizer, New York City, NY) as a positive control. Each rat received 
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one of each implant, randomized among the four incision sites. After implantation, the 
muscle incision was sutured while the skin was closed with one to three staples. 
Carprofen was also administered for two days post-operatively. Ten rats were sacrificed 
at the 4 and 10 day time points (n = 10). Satellite animals were sacrificed at the 14, 21 
and 28 day time points (n = 1) for preliminary investigation of prolonged degradation. 
Satellite animal degradation data was used for selecting degradation time points for future 
in vivo studies. After each sacrifice the implanted region and surrounding tissue were 
excised (see figure 5A) and placed in 10% phosphate buffered formalin for two days. 
Tissue sections were then bisected across the implant for quantitative and qualitative 
histological evaluation (paraffin-embedded and H&E stained). The percentages of sponge 
and fibrous tissue in the defect area of the stained tissue sections were measured and 
calculated using a Nikon inverted microscope Eclipse TE300 and BIOQUANT® OSTEO 
II image analysis software, and cellular response was graded by three blinded reviewers. 
Statistical Analysis. In vitro degradation testing was analyzed by least squares 
regression. Thermal analysis was analyzed using one-way ANOVA with Tukey’s post 
hoc analysis. In vitro biocompatibility samples were compared using an independent, two 
sample t-test. Statistical analyses on the histological results were performed initially with 
ANOVA and Holm Sidak post hoc analysis was used for the percent of fibrous tissue in 
the defect and tissue response. Statistical significance level was set at α    . 5. 
Results 
In vitro degradation. The percentage of sponge remaining over time in the in vitro 
degradation study is shown in Figure 1. Both the pH 4.6 and 5.6 buffered chitosan sponge 
formulations exhibited significant differences in degradation, 71 and 44% respectively, 
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from the neutral chitosan sponge. Although the pH 4.6 buffered chitosan sponge had a 
lower percentage of sponge remaining, there was no significant difference between the 
pH 4.6 and pH 5.6 sponge (p = 0.087). There was a significant decrease over time for the 
4.6 pH buffered chitosan sponge (p = 0.0001) and 5.6 pH buffered chitosan sponge (p = 






Figure 1. Results for the enzymatic-mediated degradation of neutral (♦), pH 5.6 buffered 
(▲), and pH 4.6 buffered () chitosan sponges represented as mean ± standard deviation 






Molecular Weight, Crystallinity, and Thermal Analysis. X-ray diffraction spectra 
(Figure 2) reveal differences between the chitosan powder, neutralized chitosan sponge, 
and buffered chitosan sponges. Characteristic diffraction peaks for chitosan powder 
appeared at 2θ of   .5° and 2 °. After manufacturing the powder into a neutralized 
chitosan sponge, the 2θ of 2 ° peak was reduced to a minimum and subsequent 
manufacturing into both buffered sponge versions eliminated this peak altogether. The  
2θ     .5° diffraction peak intensity varied between the sponge groups, but all of the 





Figure 2. Stacked x-ray diffraction (XRD) spectra in the 2θ range from 5° to 4 °of (top to 
bottom) the chitosan powder, neutral chitosan sponge, pH 5.6 buffered chitosan sponge, 






The initial molecular weight and thermal analysis of chitosan powder and 
neutralized and buffered chitosan sponges is shown in Table 1. Analysis of DSC data for 
the chitosan samples revealed that endothermic and exothermic peaks appeared at 105-
111°C and 291-326°C, respectively. The endothermic peak corresponds to water loss and 
the exothermic peak can be attributed to polymer decomposition, possibly of amine 
units.
21-23
 The chitosan powder exhibited the highest exothermic peak temperature; after 
processing chitosan into a neutral sponge, the exothermic peak temperature decreased (p 
< 0.001). Buffering the chitosan sponges at pH 5.6 and 4.6 lowered the exothermic peak 
temperature by 23.4 and 3 .2°C, respectively, from the neutral chitosan sponge’s peak 
temperature (p < 0.001).  
 
 
Table 1. Physicochemical Properties of Buffered and Unbuffered 
Chitosan Sponges and Raw Material (n = 3). 
Material  
Molecular 
Weight (kDa)  Thermal Analysis  











172.0 ± 20.76  110.1 ± 2.5  321.4 ± 0.2
*
  
pH 5.6 Buffered 
Chitosan Sponge  
220.1 ± 30.79  105.7 ± 2.4  291.2 ± 1.2
*
  
pH 4.6 Buffered 
Chitosan Sponge  










Spectral Analysis. As shown in Figure 3, several peaks characteristic of chitosan were 
identified at the following wavenumbers: H-bonded, O-H stretching at the broad peak 
centralized at 3350 cm
-1
; alkane, C-H stretching vibrations at 2910 and 2850 cm
-1
; amide 
I band C=O stretching at 1640 cm
-1
; amine and amide II band N-H bending at 1550 cm-1; 
C-H rocking at and just below 1400 cm
-1
; ether group C-O stretching at 1010 cm
-1
. All 
peaks present are typical to chitosan functional groups and buffered groups showed 
increased peak intensities and peaks shifting downward, indicative of acetate’s presence 





Figure 3. Stacked and averaged (n = 3) ATR-FTIR absorbance spectra for chitosan 






Morphology. The morphology of the chitosan powder before processing into sponges 
can be seen in Figure 4A, while the surface of the neutral, pH 5.6 and pH 4.6 buffered 
chitosan sponges can be seen in Figures 4B, C, and D, respectively. Upon inspection, the 
surfaces of both buffered chitosan sponge appear to have greater surface roughness than 
the neutral sponge. The morphology of both the pH 5.6 and 4.6 buffered chitosan sponges 













Figure 4. Scanning electron microscopy representative images of chitosan powder at 30× 
magnification (A) as well as the surface structure of the laminar sheets (at 50× 
magnification) that comprise the neutral (B), pH 5.6 buffered (C), and pH 4.6 buffered 
(D) chitosan sponges. 
 
Direct contact biocompatibility. When normalized to the polyurethane sponge control 
(Figure 5), each type of chitosan sponge caused significant decreases in biocompatibility 
after one day of direct contact treatment (p ≤  . 4 ). However, after the three day 
treatment end point, there were no significant differences between the sponge groups and 
the control. Additionally, there was no cellular malformation, degeneration, sloughing, or 
lysis and no reduction of the cell layer at the specimen perimeter upon microscopic 







Figure 5. The percent cell viability (normalized to polyurethane sponge control) after 
normal human dermal fibroblast direct contact cell viability testing of neutral, pH 5.6 
buffered and pH 4.6 buffered chitosan, and polyurethane sponges after 1 and 3 days, 
analyzed using Cell Titer-Glo Luminescent Cell Viability Assay. (n = 5, * represents p < 
0.05 versus polyurethane sponge control) 
 
In vivo degradation. Representative images from the in vivo degradation study are 
shown in Figure 6, where Figure 6A shows an implanted sponge in a rat and Figure 6B 
shows a bisected tissue block before histological processing. Histological evaluation of 
the tissue revealed some implants to be completely degraded, (Figure 6C) while others 







Figure 6. This image set depicts the surgery site and sponge retrieval (A), a bisected 
tissue section prepared for histological analysis (B), as well as representative H&E 
stained tissue sections of the control gelatin (C), neutral chitosan (D), pH 5.6 buffered 






The quantitative evaluation of the tissue histology for the percentage of implant 
area per defect area is shown in Figure 7. After 4 and 10 days of sponge implantation in 
the back muscle pouches of rats, none of the experimental groups, with regard to time 
and sponge type, exhibited significant differences in percent of implant area per defect 
area (p = 0.0856). Although not statistically different, all three types of chitosan sponge 
had 5.1-5.6% and 0.3-1.6% lower average percentage of implant in the defect after 4 and 
10 days than the control gelatin sponges. Both qualitative and quantitative evaluation of 
the fibrous tissue present around the implants revealed a wide variability in fibrous tissue 
response between surgical sites. After 10 days of implantation, the pH 5.6 buffered 
sponges exhibited a 37.08% increase in fibrous tissue present in the defect (figure 8) over 







Figure 7. A histological analysis boxplot of the percent of gelatin, neutral chitosan, pH 
5.6 buffered chitosan and pH 4.6 buffered chitosan sponge implants remaining in the 











Figure 8. A histological analysis boxplot of the percent of fibrous tissue present in the 
defect area for gelatin, neutral chitosan, pH 5.6 buffered chitosan and pH 4.6 buffered 
chitosan sponge implants, 4 and 10 days after surgery. (* represents p < 0.05 versus each 
other, ˟ represents a data point outside of the standard deviation) 
 
 
The only chitosan sponge type which demonstrated complete degradation in vivo 
was the pH 4.6 buffered chitosan sponge (n = 1) after the satellite time point of 21 days 
implantation (Table 2). The pH 4.6 buffered chitosan sponge was present after 28 days of 
implantation in a different satellite animal, with 17.28% implant in the defect. There was 
no percent implant data for the pH 4.6 and 5.6 buffered chitosan sponges at days 14, 14 
and 21, respectively as they may have been lost in histological processing. Based on 
similar photographs and tissue histology, the gelatin sponge is believed to have 






Table 2. Quantitative and qualitative analysis of satellite animal rat tissue histology after 
14, 21, and 28 days of sponge implantation ,  
Sponge  Time (days)  
% Implant 
Area/ 
Defect Area  
% Fibrous 
Tissue/ 









   
   
14  13.36  33.06  1.7 ± 0.6  Yes  
21  24  53.03  1.9 ± 0.1  Yes  




14  8.81  13.22  1.7 ± 0.8  Yes  
21  5.88  30.78  3.4 ± 0.7  Yes  





14  0  0  1.3 ± 0.6  Yes  
21  0  0  1.4 ± 0.4  Yes  





14  0  0  1.4 ± 0.5  Yes  
21  0  0  1.2 ± 1.0  No  
28  17.28  36.82  3.8 ± 0.2  Yes  
Data is reported as mean ± standard deviation (n = 1 ) and tissue response is averaged 




 After 4 days, tissue inflammatory response from the pH 5.6 and pH 4.6 buffered 
chitosan sponges was significantly higher than the tissue response from gelatin sponges 
(p = 0.029 and p < 0.001, Figure 9). After 10 days of implantation, tissue response was an 
average of 1.98 to 2.11 grades lower from gelatin sponges than from all three types of 
chitosan sponges (p < 0.001). Cellular response was not significantly different between 
chitosan sponges, either neutral or buffered, at either time point. However, a highly 
variable response was observed for all three histophotometry measures: percentage 







Figure 9. A histological analysis boxplot of the graded inflammatory response to the 
gelatin, neutral chitosan, pH 5.6 buffered chitosan and pH 4.6 buffered chitosan sponge 
implants, 4 and 10 days after surgery. Individual histological sections were scored (using 
increments of 0.25) where 0 indicated a missing or minimal implant and minimal 
response,  ‒2 indicated mild leukocyte density, 2‒3 indicated a slightly elevated response 
around the implant, 3‒4 indicated a moderate cell response, and 4‒5 indicated a high cell 
density in and around the implant. (* represents p < 0.05 versus each other at each time 





Our results show that the incorporation of a sodium acetate buffer into a chitosan 
sponge manufacturing process does significantly affect sponge material properties, 
especially increasing in vitro degradation; however, it does not affect in vitro 
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biocompatibility or in vivo degradation in rat intramuscular tissue. Evidence that the 
buffer affects in vitro sponge degradation is that both buffered sponge formulations 
degraded significantly in mass, with 18 and 42% of the pH 4.6 and pH 5.6 buffered 
chitosan sponges remaining after ten days, respectively, compared to the neutral sponge, 
with 100% sponge remaining. The buffering process at pH 4.6 reduced the sponge’s 
molecular weight by 0.5%, compared to the neutralized sponge. Although not significant, 
this decrease is important because the literature indicates that in vivo degradation is 
directly proportional to its molecular weight.
24,25
 While a decrease in molecular weight 
was found in the chitosan sponges from the powder, the pH 5.6 buffered sponge exhibited 
a surprising increase in molecular weight from the neutral sponges.   
Chitosan’s DDA and crystallinity have both been previously shown to be 
inversely proportional to chitosan’s degradation in vitro.
34,35
 Similar to other reported 
findings,
29
 crystallinity analysis of the neutral and buffered sponges indicated that our 
manufacturing, specifically the lyophilization process, decreased crystallinity from the 
initial chitosan powder. 
Thermal analysis of the chitosan powder and sponges indicated that the chitosan 
lyophilization and neutralization procedure decreased exothermic peak temperatures, 
corresponding to amine decomposition and a decrease in crystallinity.
23
 The exothermic 
peak temperature decreased by 23.4°C and 30.2°C upon the addition of the buffering step 
which may correspond to a decrease in molecular weight from chitosan powder, a 
relationship shown in other investigations,
30,36
 similar to our findings of decreased sponge 
molecular weight for the pH 4.6 buffered chitosan sponge and decreased crystallinity for 
both buffered sponges.  
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Our chemical analysis confirmed the various standard absorbance peaks of 
chitosan were present in the sponges,
26
 along with the presence of acetate functional 
groups in the buffered sponges as seen in other similar investigations.
27,28
 Although 
another researcher has reported the appearance of a carboxylic acid peak from chitosan at 
approximately 1750 cm
-1
 Nunthanid et al did not see this carboxylic acid peak in either 
chitosan flakes or chitosan acetate which corroborates our findings.
27 
  
Morphological differences were seen in surface SEM images of the neutral and 
buffered chitosan sponges. The apparent increase in surface roughness of both buffered 
chitosan sponges, as compared to the neutral sponge, may be the physical manifestation 
of changes in the chitosan’s molecular weight and crystallinity, and therefore may also be 
related to an increase in in vitro degradation. Other studies of composite acid films 
similarly produced increased surface roughness with increased acid incorporation in 
chitosan films.
40
 Both buffered sponges exhibited similar morphology, indicating little 
effect of the buffer’s pH on surface morphology. The similarities in chitosan sponge edge 
and corner morphology of the neutral and buffered chitosan sponges indicate that all of 
the sponges have a similar internal layering of chitosan layers, an example of which may 
be seen in a previous publication.
25
  
A review of the literature indicates that higher DDAs and molecular weight both 
improve cytocompatibility and cell attachment.
29
 All of the chitosan sponges exhibited 
similar molecular weights and hence similar in vitro cell response. While cellular 
compatibility levels in the literature fluctuate in direct contact assays largely due to the 
positive control selection and exposure time, our results show similar fluctuations over 
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time, where cell viability increased from one to three days,  to those found for other 
chitosan materials and applications.
18,30
  
Chitosan is reported to be biocompatible and biodegradable
29
, however there have 
been few studies performed using chitosan with only minimal modifications such as the 
buffer procedure, administered by routes other than orally, for assessing biodegradation 
and biocompatibility. In those studies that have been reported, chitosan in vivo 
degradation is described as being dependent on molecular weight,
43
 and becomes 
localized in the liver after intravenous injections.
44
 In other studies, chitosan has been 
reported as having minimal degradation after subcutaneous implantation,
45
 or rapid 
degradation after use as a wound dressing.
23
 These disparate findings led us to develop 
this screening animal model as an evaluation method for our chitosan sponge device. 
There was a wide variation in results, which lead to neither the neutral nor buffered 
chitosan sponges showing significant differences in percentage of implant in defect from 
the gelatin sponges, which served as a positive control of degradation. While there was 
wide variability in the percent implant in defect of the gelatin sponges, more of the 
gelatin sponges completely degraded than the chitosan sponges, confirming that sponge 
degradation could be determined with this animal model.  
Chitosan sponges exhibited statistically similar inflammatory tissue responses, but 
there was an increase in inflammatory response in the pH 4.6 buffered sponges at day 4, 
as compared to the pH 5.6 buffered chitosan sponges. However, this inflammatory 
response difference narrowed at day 10 of implantation. The pH 4.6 buffered sponges 
could be more acidic and would explain the increased inflammatory response than the pH 
5.6 buffered sponges in the rat muscle tissue. This result is similar to the moderate 
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inflammatory response observed in an in vivo study with Sprague-Dawley rats of chitosan 
coated, via silane-gluteraldehyde linkage, to titanium with histological images seemingly 
comparable to inflammatory responses as seen caused by the chitosan sponges.
46
 
Although there were no significant differences in percent implant in the defect 
between the chitosan sponges after 10 days, which was a surprising finding in 
comparison to the time course of the in vitro study, a few key differences could be seen in 
the satellite animals (days 14, 21, and 28). Because the pH 4.6 buffered chitosan sponges 
completely degraded after 21 days of implantation, this time point seems to be a more 
realistic estimate of the time course of complete in vivo degradation. However, the 
presence of the pH 4.6 buffered chitosan sponge after 28 days of implantation indicates 
that in future extended in vivo studies, some of these buffered sponges might still remain 
after 21 days. This degradation time may not be ideal because the chitosan sponges 
typically release most of the loaded antibiotics early.
22 
 
The available chitosan literature does not report many details on in vivo chitosan 
degradation, and the in vivo degradation and elimination mechanism is still not well 
understood. In the literature, there is molecular weight dependence for timely in vivo 
degradation and elimination, while an increase in DDA and molecular weight may 
provide for better biocompatibility.
34,47,48
 Our results indicate that the modified chitosan 
sponge is biocompatible and is degrading in this screening model. From the chitosan 
literature, the determination and achieving a desired in vivo degradation rate will require 
balancing between the chitosan’s molecular weight, DDA, crystallinity, and the applied 
manufacturing methods. Future work is needed and planned to define the in vivo 
degradation profile of current chitosan sponge devices over an extended period of time so 
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that the further development of the chitosan sponge may provide an alternative option for 
the adjunctive therapy of contaminated musculoskeletal wounds.  
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PRELIMINARY EVALUATION OF CHITOSAN AND POLYETHYLENE 
GLYCOL BLENDED SPONGES FOR THE IN VITRO LOCAL DELIVERY OF 
AMPHOTERICIN B AND IN VIVO DEGRADATION IN A RAT 
INTRAMUSCULAR MODEL 
Introduction 
Infection associated with musculoskeletal extremity injuries has a significant 
impact on patient morbidity and mortality and can be a devastating complication.  Open 
extremity injuries are especially susceptible to multiple pathogenic, and sometimes drug 
resistant, bacteria or fungi.
1
 Invasive fungal infections have recently become especially 
troublesome for both military and civilian populations, with high mortality rates and high 
healthcare costs.
2-4
  The British Military has recently reported higher rates of fungal 
wound infections in casualties from the Helmand Province in Afghanistan.
5
  In a 2011 
Trauma Infectious Disease Outcome Study, 36 cases of invasive fungal infections (IFI) 
were found in Operation Enduring Freedom soldiers with blast injuries in Afghanistan 
from June 2009 to December 2010, and 78% of these wounded soldiers with IFI required 
lower extremity amputations.
6
  An outbreak of cutaneous mucormycosis was also 
recently reported in victims from the 2011 tornado in Joplin, Missouri.
7,8
  Apophysomyces 
trapeziformis was identified in all 13 infected patients, 10 patients required admission to 
intensive care, and 5 of these patients died.
7,8
  Finally, invasive Candida infections are 
the third most common cause of hospital-acquired bloodstream infections.
9
   
The current standard of care for invasive fungal infections is systemic antifungal 
delivery, and antifungals utilized for invasive fungal infection management include 
triazoles, polyenes (amphotericin B), echinocandins, and flucytosine.
10
 Although the 
Infectious Disease Society of America advocates the use of voriconazole over traditional 
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amphotericin B as the primary treatment of Aspergillus infections, both azole resistant 
Aspergillus and Candida have emerged (as well as echinocandin resistant Candida).
11
 
Amphotericin B is one of the most commonly used antifungals in clinical practice and 
fungal resistance to the antifungal has not emerged over 50 years.
11
  However, systemic 




While antibiotics have been studied extensively in local delivery, antifungals have 
not been successfully locally delivered from as many degradable delivery systems 
because of their hydrophobicity for loading and distribution.  Amphotericin B has been 
incorporated into a few local delivery systems, including polymethylmethacrylate 
(PMMA) bone cement
12-14
, a hydroxyapatite and chitosan composite
15
, a Pluronic® based 
copolymer gel
16
, and dextran hydrogels
17,18
. Although PMMA is commonly used for 
local antibiotic delivery, there is conflicting data on its release of amphotericin B.
12-14
 
Goss and researchers found an absence of amphotericin B release from bone cement, 
while Kweon et al. reported 0.05-0.45% release of the antifungal and Marra and 
researchers found amphotericin B concentrations to be 3.2 µg/mL in surgical wound 
fluid.
12-14
   Additionally, all of these local antifungal delivery systems are pre-loaded with 
antifungal. A local degradable delivery system that is capable of rapid point of care 
loading would allow the clinician to select the appropriate antimicrobial (or 
antimicrobials) and dosage, based on each individual patient’s needs.  
Previous research conducted at the University of Memphis has yielded a topical, 
porous, degradable chitosan sponge that provides an adaptable antibiotic delivery system 
in which tailored dosing and degradation can be achieved.
1-5
 This system can be loaded 
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with antibiotics immediately prior to use, allowing for clinician selected antibiotic 
loading, as well as combination loading.
1-5
   Additional previous research has also shown 
that using polyethylene glycol (PEG) as a solvent system for a hydrophobic fatty acid, 
cis-2-decenoic acid, allows for point of care loading of the fatty acid into the chitosan 
sponges.
5
  Polyethylene glycol is a water soluble polymer that exhibits protein resistance 
and low toxicity and immunogenicity.
6
  PEG has been used to modify chitosan films, 
fibers, and hydrogels, and chitosan can be blended or copolymerized with PEG.
6-9
  
Polyethylene glycol has also been utilized as a solvent system, either as liposomes or 
nanoparticles, for amphotericin B in systemic delivery.
10-13
    
We hypothesized that creating chitosan/PEG blended sponges would result in 
increased in vitro amphotericin B release, cytocompatibility, and in vitro and in vivo 
sponge degradation, as compared to control chitosan sponges. The first aim of this study 
was to evaluate the effect of adding PEG to the chitosan sponges on spectroscopic, 
morphologic, thermal, and crystalline material properties, as well as in vitro degradation, 
antifungal release, eluate fungal activity, and cytocompatibility. The second aim of the 
study was to evaluate the in vivo degradation and biocompatibility of chitosan/PEG 
sponges and control chitosan sponges in a rat dorsal muscle pouch model, using 
qualitative and quantitative histological assessment of the implant sites. 
Materials and Methods 
Fabrication. Chitosan was purchased from Chinitor AS (Tromsway, Norway) with a 
average molecular weight of 250.6 kDA and 82.46 ± 1.679 degree of deacetylation 
(DDA).  Polyethylene glycol (PEG) was obtained from Sigma Aldrich at two different 
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molecular weights, 6,000 g/mol and 8,000 g/mol.  Acetic acid and sodium hydroxide 
(NaOH) were both purchased from Fisher Scientific (Pittsburgh, PA).   
To make chitosan and PEG sponges, 0.5% (w/v) of PEG (6,000 or 8,000 g/mol) 
was dissolved in a 1% (v/v) acetic acid in water solution.  After PEG dissolution, 0.5% 
(w/v) of chitosan was dissolved in the same solution.  Chitosan sponges were 
manufactured by dissolving 1% (w/v) chitosan in the 1% acetic acid solution.  Solutions 
were mixed on a stirplate for approximately one hour, and then 25 mL of the solution was 
poured into 42 mL aluminum pans.  The sponges were frozen for at least one hour at        
-80°C and then lyophilized (lyo) in a LabConco (Kansas City, MO) FreeZone 2.5 Liter 
Benchtop Freeze Dry System.   
After the first lyophilization, the 1% chitosan sponges were neutralized in 0.6 M 
NaOH, by soaking the sponges in the base solution for approximately 1-2 minutes and 
then washing the sponges in large amounts of water until a neutral pH was reached.  The 
concentrations of NaOH solutions were determined through previous formulation testing. 
Some of the chitosan/PEG sponges were neutralized in 0.25 M NaOH (the 2 
lyophilization groups), while other chitosan/PEG sponges were not neutralized at all (the 
1 lyophilization groups).  After neutralization, the sponges were frozen again at -80°C 
and lyophilized one last time. All sponges were sterilized via low dose gamma irradiation 
at a 25-40 kGy dosage.  
FTIR. Functional group chemistry differences between the sponges were evaluated using 
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR). A 
ThermoScientific (Waltham, MA) Nicolet iS10 FTIR spectrometer with a diamond ATR 
crystal was used to acquire the absorbance spectra (n = 3), using 64 scans with a 
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resolution of 4 cm
-1
. The spectra were averaged and analyzed with the Thermo Scientific 
OMNIC
TM
 Software Suite. 
XRD. X-ray diffraction (XRD) was used to define the crystal structure of the chitosan 
and chitosan/PEG sponges. A Bruker AXS (Maddison, WI) Advanced D8 X-ray 
diffractometer was utilized to obtain X-ray diffraction patterns with a Kα Cu radiation 
source at 40 kV and 40 mA. XRD data was obtained over a 2θ range from 5° to 40° with 
a time/step of 0.2 seconds and a step size of 0.05°.  
Thermal Analysis. Differential scanning calorimetry (DSC) was used to evaluate 
differences in endothermic and exothermic peaks of the chitosan powder, PEG 6000, 
PEG 8000, 1% chitosan sponges, and chitosan/PEG sponges.  A Netzsch (Selb, 
Germany) 200 PC differential scanning calorimeter was used to scan the samples (n = 3) 
from 40 to 400°C at 20°C/min.  
Morphology. Surface morphology of the chitosan and chitosan/PEG sponges was 
assessed with a FEI/Philips XL30 Environmental Scanning Electron Microscope (SEM) 
at 15 kV using samples sputter-coated with 30 nm of Au/Pd. SEM images (n = 3) were 
qualitatively evaluated for differences between sponges such as surface texture and 
porosity. 
In Vitro Degradation. To analyze the enzymatic in vitro sponge degradation, sponges 
were dried thoroughly and weighed.  The sponges were placed in 125 mL Nalgene 
(Rochester, NY) containers, along with 35 mL of 1 mg/mL 2 x crystallized chicken egg 
white lysozyme, purchased from MP Biomedicals (Santa Ana, CA).  The sponges in their 
lysozyme solutions were placed on a shaker in an incubator at 37°C. The lysozyme 
solution was completely refreshed every two days.  After 2, 4, 8, and 10 days of 
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degradation,  sponge samples were removed from the lysozyme solution (n = 3), soaked 
briefly in deionized water to stop any enzymatic degradation, dried thoroughly in a 
vacuum oven at 60°C for two days, and then reweighed.  This study was a destructive 
study, so every time point represents a different sponge sample.  




Percent remaining      
Sponge weight at   days
Initial dry sponge weight 




Indirect Molecular Weight Measurement (Viscosity). To analyze the effect of in vitro 
degradation indirectly on sponge molecular weight, the viscosity of sponges dissolved in 
sodium acetate and acetic acid was measured.  It was not possible to directly measure 
molecular weight measurement of the chitosan and PEG blends though gel permeation 
chromatography (GPC) because of different dn/dc values for chitosan and PEG.  
Chitosan and chitosan/PEG sponges from the in vitro degradation 10 day time point       
(n = 3) were dissolved in a solution of 0.1 M sodium acetate and 0.2 M acetic acid. 
Chitosan and chitosan/PEG sponges that were not included in the degradation study were 
also dissolved in the sodium acetate and acetic acid buffer (n = 3) and were considered a 
zero day time point.  A Brookfield Programmable DV-II + Viscometer with a CPE-40 
cone spindle and circulating water bath at 25°C was used to measure the viscosity of 
sponge solutions at 50 rpm.   
Antifungal Elution. To determine if the chitosan/PEG sponges would deliver antifungals 
locally in vitro, a 1 mg/mL solution of amphotericin B (Fisher Scientific) was created in 
sterile Ultrapure water.  The amphotericin B solution was shaken immediately prior to 
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loading, and 10 mL of the antifungal solution was added to the sponges (n = 3).  After 
approximately one minute, the amphotericin B solution not absorbed by the sponge was 
removed and measured.  Twenty milliliters of sterile 1 x phosphate buffered saline (PBS) 
was added to the sponges in Nalgene containers and they were then placed on a shaker in 
an incubator at 37° C.  After 1, 3, 6, 24, 48, and 72 hours of elution, four 1 mL samples 
were removed from the sponge solution and the PBS was completely refreshed. 
The concentration of amphotericin B in the eluates was measured via ultraviolet 
visible spectroscopy. To prepare the insoluble amphotericin B samples, the eluates were 
added 1:1 to dimethylsulfoxide (DMSO), purchased from Fisher Scientific.  Highly 
concentrated amphotericin B solutions, including the original 1 mg/mL solution, were 
diluted in DMSO multiple times. Amphotericin B samples were read via absorbance at 
389 nm in a Biotek (Winooski, VT) Synergy H1 plate reader and concentrations were 
calculated using an amphotericin B standard curve.   
Antifungal Activity. To determine if the amphotericin B released from the sponges 
remained active against fungi, the amphotericin B eluate samples were lyophilized in foil 
for one day.  The samples were then dissolved in 50 μL of PBS and used to inoculate 
blank discs.  Standard concentrations of amphotericin B from 0 to 2.5 μg in 0.25 μg 
increments were also used to inoculate blank discs. A 0.5 McFarland standard of Candida 
albicans in sterile PBS was prepared and a cotton swab was used to streak a Mueller 
Hinton agar plate in three different directions.  An inoculated disc was added to each 
plate and the plates were incubated overnight at 37°C.  The zone of inhibition (ZOI) was 
measured for each amphotericin B sample and a standard curve was determined.  Zone of 
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inhibition for each sample was also measured and compared to the standard curve to 
determine sample concentration.  
In Vitro Biocompatibility. The in vitro biocompatibility of both the chitosan/PEG 
sponges and the antifungal eluates was tested on normal human dermal fibroblasts 
(NHDFs), purchased from Lonza (Walkersville, MD).  A protocol modified from ASTM 
F813-07 “Standard Practice for Direct Contact Cell Culture Evaluation of Materials for 
Medical Devices” was followed in order to assess the direct contact biocompatibility 
between the chitosan sponge variations.
14
  Cells (passages 4 through 7) were seeded at 
3.66×10
4
 cells/mL (day one treatment) or 1.43 x 10
5
 cells/mL (day three treatment) and 
allowed to proliferate to near confluence on 12-well polystyrene tissue culture plates in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and penicillin (100 units/mL), streptomycin (100 mg/mL), and amphotericin 
B (0.25 µg/mL), all purchased from Fisher Scientific, under standard cell culture 
conditions (37°C and 5% CO2 atmosphere). Cell culture medium was aspirated and 
refreshed with 1 mL of fresh medium, while chitosan, chitosan/PEG, and control 
polyurethane sponges were soaked in pre-warmed, sterile 1 x PBS for approximately 20 
minutes.  A single 8 mm diameter test specimen (n = 5) was then gently placed in a well 
in direct contact with the cell monolayer.  Cultures were incubated for either one or three 
days before biocompatibility was assessed with the Cell Titer-Glo® Luminescent Cell 
Viability assay, purchased from Promega (Madison, WI).The luminescent signal, which 
corresponded to the amount of adenosine triphosphate and the number of viable cells 
through a standard dilution of known concentrations of cells, was recorded at 590 nm 
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using a BioTek (Winooski, VT) Synergy H1 (day one treatment) or a BioTek FLx-800 
Fluorescence Microplate Reader (day three treatment). 
In Vivo Degradation. In vivo degradation and biocompatibility of the chitosan and 
chitosan/PEG sponges was assessed in 13 three to four month old male Sprague-Dawley 
rats. This in vivo study was approved by the institutional review board at the University 
of Memphis (IACUC protocol #0728) and followed the IACUC guidelines. Rats were 
anesthetized with 2% isoflurane in an environmental chamber and were maintained under 
4-5% isoflurane while being prepared for sterile surgery.  Two 1.5 cm incisions were 
made through the skin on each side of the midline (4 incisions total) and a 1.25 cm pouch 
was created in the latissimus dorsi muscle in each incision. One cylindrical implant, 9.5 
mm in diameter and 5 mm in thickness, was implanted bilaterally in each muscle pouch. 
Test groups included chitosan sponge, chitosan/PEG 6000 1 lyophilization (lyo), 
chitosan/PEG 6000 2 lyo, and chitosan/PEG 8000 1 lyo sponges. Each rat received one of 
each implant, randomized among four incision sites. The muscle incision was sutured and 
the skin was closed with one to three staples. Carprofen was administered prior to surgery 
and for two days post-operatively. Five rats were sacrificed at the 4 and 10 day time 
points (n = 5), and satellite animals were sacrificed on the 14, 21 and 28 day time points 
(n = 1). The degradation data from the satellite animals served as a preliminary indication 
for longer degradation and for selecting degradation time points for future in vivo studies.  
After sacrifice, the implanted region and surrounding tissue were excised, placed in 10% 
formalin buffered phosphate (FBS) for two days, and then bisected across the implant for 
quantitative and qualitative histological evaluation (paraffin-embedded and H&E 
stained). Surgical defect areas of the stained tissue sections were measured as the 
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remaining sponge plus surrounding fibrous tissue using a Nikon inverted microscope 
Eclipse TE300 and BIOQUANT® OSTEO II image analysis software.  The area of 
sponge and fibrous tissue were measured separately, divided by defect area, and 
converted to a percentage. Qualitative histological evaluation was conducted by three 
blinded reviewers based on cellular response.  Histology was scored on a scale of 0 to 5 
(low to high) in increments of 0.25, using a modified version of the Knodell Histological 
Activity Index (HAI).
15
 Cellular response scores were 0 for no tissue for evaluation, 1 for 
very mild leukocytic density, 2 for slightly more elevated cellular response, 3 for 
moderate cellular response, 4 for high cell density in and around implant site, and 5 for 
extremely high cellular response.  
Statistical Analysis. Viscometry data was analyzed using one-way Analysis of Variance 
(ANOVA) with Holm Sidak post hoc analysis.  Thermal analysis was analyzed by one-
way ANOVA with Holm Sidak post hoc analysis, except for the endothermic peak 
temperatures and areas, which were analyzed using Kruskal-Wallis one-way ANOVA on 
ranks with Tukey’s post hoc analysis. Antifungal elution, activity and cytocompatibility 
data were analyzed using two-way ANOVA with Holm Sidak post hoc analysis.  Two-
way ANOVA was utilized to analyze the percent fibrous tissue in the defect and the 
tissue response in the in vivo rat study.  The percentage of implant in the defect in the rat 
study was analyzed using Kruskal-Wallis one-way ANOVA with Dunn post hoc analysis. 
Statistical significance level was set at α = 0.05.    
Results 
FTIR.  Results from the FTIR analysis of the chitosan/PEG blended sponges and control 
chitosan sponges are provided in Figure 1A, while Figure 1B shows the FTIR spectra of 
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chitosan powder, PEG 6000, and PEG 8000.  Characteristic peaks were seen in the 1% 
chitosan sponges at 3290 (O-H stretching), 1643 (amide I C=O stretching), and 1557 




 Characteristic C-O bending peaks were seen in PEG 6000 and 





   
All blended sponges exhibited the characteristic chitosan peaks at 3357-3360   
cm
-1
, and all peaks were shifted to higher wavelengths compared to the 1% chitosan 
sponges.  Characteristic chitosan peaks at approximately 1643 and 1557 cm
-1
 were also 
seen in all blended sponges. All sponges and PEG also exhibited peaks at approximately 
1145-1149 cm
-1
 (C-O stretching), where the peaks in the spectra of both 1 lyophilization 
blended sponges, PEG 6000, and PEG 8000 were at lower wavelength than the 1% 
chitosan sponge and 2 lyophilization blended sponges.
16
 Both the chitosan/PEG 6000 1 
lyo and 8000 1 lyo sponges exhibited the peaks seen in PEG at 1279 and 1099 cm
-1
, but 
neither blended sponges with 2 lyophilizations nor the chitosan sponges exhibited these 
peaks.  All of the blended sponges, except for the chitosan/PEG 6000 2 lyo sponge, 
showed the peak from PEG at 960-962 cm
-1
.  All sponges exhibited the peak at 840-843 
cm
-1
, but both blended sponges with 1 lyophilization and PEG had peaks with higher 











Figure 1. Stacked and averaged (n = 3) ATR-FTIR absorbance spectra for (A) I. 
chitosan/PEG 6000 1 lyo, II. chitosan/PEG 8000 1 lyo, III. chitosan/PEG 8000 2 lyo, IV. 
chitosan/PEG 6000 2 lyo, and V. 1% chitosan sponges, and (B) I. chitosan powder, II. 






XRD.  X-ray diffraction results (Figure 2A) reveal a difference between the chitosan 
powder and all sponge types.  The chitosan powder exhibited the typical crystalline peak 
at approximately 20°, but this peak disappeared upon manufacturing the powder into 
sponges, both in the control chitosan sponges or the chitosan/PEG blended sponges.  
Additionally, the peak at approximately 12° in the chitosan powder decreases upon 
sponge manufacturing, and the 1% chitosan, chitosan/PEG 6000 2 lyo, and chitosan/PEG 
8000 1 lyo sponges displayed the smaller peaks.  A very small peak can be seen in the 
chitosan/PEG 6000 1 lyo sponge at 24°, which is a contribution from the crystalline peak 









Figure 2. (A) Stacked x-ray diffraction (XRD) spectra in the 2θ range from 5° to 40°of 
(top to bottom) the chitosan powder, chitosan/PEG 6000 1 lyo sponge, chitosan/PEG 
8000 2 lyo sponge, chitosan/PEG 6000 2 lyo sponge, 1% chitosan sponge, and 
chitosan/PEG 8000 1 lyo sponge, and XRD spectra in the 2θ range from 5° to 40° of (B) 






DSC.  The DSC data for the chitosan/PEG and chitosan sponges, and chitosan, PEG 




Table 1. Differential scanning calorimetry results of chitosan/PEG and chitosan sponges, 
as well as chitosan, PEG 6000, and PEG 8000 powder.  
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56.0 ± 1.0
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6000 2 Lyo 
110.8 ± 4.8 1.1 ± 0.1 -191.8 ± 
28.9 
319.5 ± 1.1 2.3 ± 0.3 169.7 ± 
22.0 
Chit/PEG 
8000 1 Lyo 













8000 2 Lyo 
122.9 ± 9.2
γ
 1.1 ± 0.1 -200.7 ± 
9.5 







 1.1 ± 0.04 -210.5 ± 
12.0 








   3.3 ± 0.1
‡
 178.7 ± 
8.6 




N/A N/A N/A 








indicate p < 0.05 vs. each other,
*









Analysis of the thermal data revealed that endothermic and exothermic peaks 
appeared at 56-126°C and 313-319°C in the sponges and powder samples. The 
endothermic peak can be attributed to water loss, while the exothermic peak corresponds 
to the decomposition of amine units.
17-19
 Because the PEG 6000 and 8000 powder 
samples do not have amine units, both are lacking the exothermic peak. The chitosan 
powder had the highest exothermic peak temperature, but after processing the chitosan 
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into a 1% chitosan sponge, the exothermic peak temperature decreased by 6.8°C (p < 
0.001).  The chitosan/PEG 2 lyo sponges also exhibited similar exothermic peak 
temperatures to the 1% chitosan sponge.  However, the chitosan/PEG 6000 and 8000 1 
lyo sponges exhibited 5.44°C and 3.77°C lower exothermic peak temperatures than the 
1% chitosan sponge (p < 0.001 and p = 0.008).  Additionally, the height and area of the 
exothermic peaks in the chitosan/PEG 1 lyo sponges also decreased significantly from the 
chitosan/PEG 2 lyo and 1% chitosan sponges.  The chitosan/PEG 1 lyo sponges also 
exhibited lower endothermic peak temperatures and areas than the chitosan/PEG 2 lyo 
sponges, 1% chitosan sponges, and chitosan powder.   
SEM. The morphology of the cross-sections of the 1% chitosan sponges and 
chitosan/PEG blended sponges can be seen in Figure 3A-E, while the surface structure of 
the 1% chitosan sponges and chitosan/PEG blended sponges can be seen in Figure 3F-J.  
The cross-sections of all sponges do not appear to be significantly different. However, the 
surface of the 1% chitosan sponge appears to have the greatest surface roughness, with 
the chitosan/PEG 6000 1 lyo and chitosan/PEG 8000 1 lyo sponges exhibiting a slight 
decrease in surface roughness.  In the chitosan/PEG 8000 2 lyo sponge, only a few visible 






Figure 3. Representative scanning electron microscopy of sponge cross sections at 30× 
magnification: (A) 1% chitosan, (B) chitosan/PEG 6000 1 lyo, (C) chitosan/PEG 6000 2 
lyo, (D) chitosan/PEG 8000 1 lyo, and (E) chitosan/PEG 8000 2 lyo sponges, as well as 
sponge surface structure at 30× magnification of (F) 1% chitosan, (G) chitosan/PEG 6000 
1 lyo, (H) chitosan/PEG 6000 2 lyo, (I) chitosan/PEG 8000 1 lyo, and (J) chitosan/PEG 






In vitro degradation and viscosity. Results from the in vitro degradation study of the 
chitosan/PEG blended sponges and control chitosan sponges are provided in Figures 4A 
and 4B.   The chitosan/PEG 6000 1 lyo, chitosan/PEG 6000 2 lyo, and chitosan/PEG 
8000 1 lyo sponges exhibited significant differences in degradation, 58.99, 31.11, and 
94.18% respectively, than the control chitosan sponge, as well as 49.37, 21.59, and 
84.66% less sponge remaining than the chitosan/PEG 8000 2 lyo sponge (Figure 4A). 
There was no significant decrease in remaining sponge over time for any of the 












Figure 4.(A) Percent sponge remaining (mean ± standard deviation) of chitosan/PEG 
6000 1 lyo (○), chitosan/PEG 6000 2 lyo (■), chitosan/PEG 8000 1 lyo (▲), 
chitosan/PEG 8000 2 lyo (♦), and 1% chitosan () sponges after 2, 4, 8, or 10 days of in 
vitro enzymatic-mediated degradation (n = 3), where at each time point, * indicates p < 
0.05 versus 1% chitosan, † denotes p < 0.05 versus chitosan/PEG 8000 2 lyo, ** indicates 
p < 0.05 versus all, and ‡ represents p < 0.05 versus all except §. (B) Brookfield viscosity 
measurements of sponges dissolved in 0.1 M sodium acetate and 0.2 M acetic acid before 
degradation (day 0) and after enzymatic-mediated degradation (day 10), where * denotes 






Viscosity measurements were used in order to indirectly evaluate possible 
molecular weight changes of the blended polymer sponges after degradation; direct 
molecular weight measurements were not possible through GPC.  All of the sponges, 
except for the chitosan/PEG 6000 2 lyo sponges, exhibited a decrease in viscosity from 
day 0 to day 10 of degradation (Figure 4B), although only the chitosan/PEG 8000 2 lyo 
sponge exhibited a statistically significant difference (p = 0.014).  
In Vitro Amphotericin B Elution.  The in vitro amphotericin B release from the 
chitosan/PEG and chitosan sponges is reported in Figure 5.  The average concentrations 
of amphotericin B released from all sponges after 1 and 3 hours were all above the 
minimum inhibitory concentration (MIC) for Candida albicans, but not for all later time 
points.  The chitosan/PEG 6000 1 lyo sponge was the only sponge formulation to release 
amphotericin B at levels above the C. albicans MIC throughout the entire 72 hour 
elution.  The chitosan/PEG 6000 and 8000 2 lyo sponges released average amphotericin 
B concentrations above the MIC at 72 hours, but not for all earlier time points.   After 1 
hour of elution, the chitosan/PEG 6000 1 lyo sponge released 20.41, 11.88, 19.34, and 
23.60 more μg/mL of amphotericin B than the chitosan/PEG 6000 2 lyo, chitosan/PEG 
8000 1 lyo, chitosan/PEG 8000 2 lyo, and 1% chitosan sponges, respectively. The 
chitosan/PEG 8000 1 lyo sponge also released 8.53, 7.46, and 7.91 more μg/mL of 
antifungal after 1 hour than the chitosan/PEG 6000 2 lyo, chitosan/PEG 8000 2 lyo, and 
1% chitosan sponges, respectively. The cumulative percent release of loaded 
amphotericin B after 72 hours was determined to be 12.4 ± 3.8, 5.3 ± 3.6, 5.2 ± 0.3, 5.4 ± 
2.1, and 7.7 ± 2.2% for the chitosan/PEG 6000 1 lyo, 6000 2 lyo, 8000 2 lyo, and 1% 
57 
 
chitosan sponges, respectively. While the chitosan/PEG 1 lyo, and 1% chitosan sponges 
exhibited significant differences in antifungal elution over time, the chitosan/PEG 2 lyo 
sponges did not release significantly different concentrations of amphotericin B over 
time.    
Antifungal Activity. Results from the antifungal activity zone of inhibition assay can be 
seen in Figure 6, reported as amphotericin B concentration in μg/mL.  All of the selected 
amphotericin B eluates tested in the assay had sufficient corresponding activity on 
Candida albicans, except for the eluates from the 1% chitosan sponges.  Some of the 
amphotericin B eluates released from the 1% chitosan sponges that were measured at 
levels above the C. albicans MIC did not inhibit growth of C. albicans in the ZOI assay.  
In the ZOI assay, the eluates from the chitosan/PEG 6000 1 lyo and 8000 1 lyo sponges 
had the highest C. albicans zone of inhibition and corresponding amphotericin B 
concentration, and were both significantly different from the 1% chitosan sponges after 6 













Figure 5. Amphotericin B released in vitro in µg/mL (mean ± standard deviation) from 
sponges over time and the minimum inhibitory concentration of amphotericin B for 
Candida albicans, where * represents p < 0.001 versus chit/PEG 6000 1 lyo 1 hour time 
point, † denotes p < 0.003 versus chit/PEG 8000 1 lyo 1 hour time point, δ indicates p < 
0.05 versus 1% chitosan 1 hour time point, ** represents p < 0.001 versus all sponge 
groups within the time point, and †† denotes p < 0.007 versus all sponge groups within 




















Figure 6. Results from antifungal activity zone of inhibition assay using selected 
amphotericin B eluted from chitosan/PEG and 1% chitosan sponges, where * indicates    




Cytocompatibility.  As seen in Figure 7, each type of sponge caused significant 
decreases in cytocompatibility from the control polyurethane sponge, where the control 







Figure 7. Direct contact biocompatibility normalized to polyurethane sponge control, 
represented in mean percent cell viability ± standard deviation, of normal human dermal 
fibroblasts after exposure to polyurethane, chitosan/PEG, and 1% chitosan sponges for 
one and three days, analyzed using Cell Titer-Glo® luminescent assay (* indicates p < 




After 1 day, the 1% chitosan sponge and chitosan/PEG 8000 2 lyo sponges 
exhibited the largest decreases in percent cell viability, with 39 and 28.57% reduction in 
cell viability from the polyurethane control, respectively.  Upon microscopic examination 
after one day of treatment, both the 1% chitosan and chitosan/PEG 8000 2 lyo sponges 
exhibited slight cellular malformation changes in some fibroblasts, while the other 
blended sponges did not cause any visible changes to the cells from the control. However, 
after three days of treatment, there were no significant differences between any of the 
sponges and the polyurethane sponge control.  After three days of treatment, the cellular 
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morphology that was visible after day one for some of the sponges was no longer present.   
Additionally, these cytocompatibility evaluations found no sloughing, lysis, or reduction 
of the cell layer at either time point.  
In Vivo Degradation and Biocompatibility.  Data from the quantitative and qualitative 
evaluation of the rat tissue histology is shown in Figures 8-10. The percentage of implant 
area per defect area after 4 and 10 days of implantation is shown in Figure 8, but none of 
the experimental groups, with regard to time, exhibited significant differences (p = 
0.449). The control 1% chitosan sponges and chitosan/PEG 6000 1 lyo sponges did 
exhibit significant differences in percent implant after 4 days of implantation (p = 0.001). 
None of the sponges degraded completely after 10 days. Quantitative and qualitative 
evaluation of fibrous tissue present around the sponges revealed a wide variability 
between surgical sites (Figure 9).  Additionally, there were no statistically significant 
differences in percent fibrous tissue area per defect area between any of the sponges, with 




Figure 8. Histological analysis boxplot of the percentage of sponge implants present in 
the defect area, 4 and 10 days after surgery (+ and ○ represents the mean and a data point 







Figure 9. Histological analysis boxplot of the percentage of fibrous tissue present in the 













After 4 days of implantation, the chitosan/PEG 8000 1 lyo sponge exhibited the 
lowest average tissue response of the blended sponges (Figure 10), although not 
statistically different (p = 0.336).  Similar to the implant percentage results, the 
chitosan/PEG 6000 1 lyo sponge displayed the highest average tissue response of all the 
sponges.  After 10 days of implantation, the average tissue response increased by 5, 4, 5, 
and 72% for the 1% chitosan, chitosan/PEG 6000 1 lyo, chitosan/PEG 6000 2 lyo, and 










Figure 10. Histological analysis boxplot of the average graded inflammatory response 
from three blinded reviewers (+ and ○ represents the mean and a data point outside of the 













In the satellite animals, none of the chitosan/PEG blended sponges nor the 
chitosan sponges degraded completely after 14, 21, or 28 days (Table 2).  However, the 
chitosan/PEG sponges exhibited decreases in percent implant from 10 days to 28 days, 
and the chitosan/PEG 6000 2 lyo sponge demonstrated the largest decrease in implant 
percentage with an 88.77% reduction in percent implant from 10 to 28 days of 
implantation. While there is no data for the percentage of chitosan/PEG 6000 1 lyo 
sponge in defect after 14 days, the sponge was present in the original tissue block, so it is 




Table 2. Quantitative and qualitative analysis of satellite animal rat tissue histology after 
14, 21, and 28 days of sponge implantation  












Tissue Block  
Chitosan/PEG 
6000 1 Lyo 
Sponge  
14  0 0 1.33 ± 0.14  Yes  
21  27.55  27.55  2.5 ± 0.5  Yes  
28  9.58 9.58 2.08 ± 1.01  Yes 
Chitosan/PEG 
6000 2 Lyo 
Sponge  
14  14.25 17.53 3.08 ± 0.88  Yes  
21  5.78 15.51  2.75 ± 0.90  Yes  
28  1.76  5.01  1.67 ± 1.61  Yes  
Chitosan/PEG 
8000 1 Lyo 
Sponge  
14  8.52 10.33 3.33 ± 0.58  Yes  
21  14.72 24.96 3.5 ± 0.25  Yes  
28  8.13 12.05  1.83 ± 1.04  Yes  
1% Chitosan 
Sponge  
14  4.02 27.9 4 ± 0.25  Yes  
21  7.08 28.19 3.75 ± 0.43  Yes 
28  21.58 23.6  2 ± 0.5  Yes  
Data is reported as mean ± standard deviation (n = 1) and tissue response is averaged 







 These experimental results demonstrate that blending chitosan with polyethylene 
glycol in sponge form does significantly affect sponge material properties, amphotericin 
B elution, antifungal activity, and in vivo degradation in rat intramuscular tissue. 
However, blending does not affect in vitro cytocompatibility or in vivo biocompatibility 
in rat tissue.  The presence of characteristic PEG peaks at 1279, 1099, 960, and 842 cm
-1
 
in both 1 lyo chitosan/PEG blended sponges confirm the presence of PEG in the sponges.  
Although these peaks are not present in the 2 lyophilization blended sponges, the peak 
shift to lower wavelength at 842 cm
-1
 in the 2 lyophilization sponges, as compared to 843 
cm
-1
 in the 1% chitosan sponge, indicates the possibility of residual PEG and possible 
interaction between chitosan and PEG. The chitosan/PEG 8000 2 lyo blended sponge also 
exhibited the characteristic PEG peak at 962 cm
-1
, which indicates this blended sponge 
may have more PEG present in the sponge than the 6000 2 lyo sponge, which did not 
exhibit the peak.  The FTIR spectra of the blended sponges in this study did not 
demonstrate a disappearance or shift of the amide I band to lower wavelength, as reported 
in previous research.
7,8
  However, all blended sponges, except for the 6000 2 lyo sponge, 
exhibited decreased absorbance of the amide I peak at 1643 cm
-1
. The chitosan/PEG 1 lyo 
sponge also demonstrated both a shift of the amide II N-H peak at 1557 cm
-1
 to lower 
wavelength and increased absorbance compared to the chitosan sponge, which has also 
been confirmed by previous studies.
7,8
 
 Analysis of the XRD spectra revealed that the chitosan powder exhibited a 
hydrated crystalline peak at 2θ = 10° and a sharp hydrated crystalline peak at 2θ = 20°, 
indicating the presence of anhydrous chitosan crystal structure.
20
  After chitosan 
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dissolution and lyophilization, the crystalline peak at 20° disappeared and the 10° peak 
decreased and became broader, suggesting a large loss in helical crystalline forms.
21
 
Additionally, the increase of the peak and its sharpness at 2θ = 7° in the sponges from the 
powder indicates there could be some reordering of the polymer chains.  Because of the 
increased 10° peak in both the chitosan/PEG 6000 1 lyo and 8000 2 lyo sponges and the 
presence of the small PEG crystalline peak at approximately 24° in the chitosan/PEG 
6000 1 lyo sponge, both of these blended sponges appeared to exhibit increased 
crystallinity from the other blended and control chitosan sponges.  The chitosan/PEG 
6000 2 lyo and 8000 1 lyo sponges only showed a slightly reduced 10° peak from the 





. Similar to this study, Wang et al. also found chitosan/PEG 
blended fibers to be absent of PEG crystalline peaks in XRD spectra.
7
 
 Thermal analysis of the chitosan powder, sponges, and chitosan/PEG blended 
sponges indicated that the chitosan double lyophilization and neutralization procedure 
decreased exothermic peak temperatures, which corresponded to amine decomposition.
19
  
Additionally, the one lyophilization procedure for some of the chitosan/PEG sponges 
decreased the exothermic peak temperatures even further, by up to 5.5°C from the 
chitosan powder, and decreased the exothermic peak height and area as well. This shift of 
the exothermic peak to lower temperatures in the 1 lyo sponges is similar to previously 
reported findings that, with increasing PEG content in chitosan and PEG blended films, 
the exothermic peak temperature shifted to lower temperatures.
16
  Additionally, the 
decreased endothermic peak temperatures (56.03 and 58.57°C) in the chitosan/PEG 1 lyo 
sponges can be attributed to the melting temperature of PEG 6000 and 8000, 
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approximately 68°C. The shift to even lower endothermic peak temperatures can be 




 Morphological differences were seen in surface SEM images, but not cross-
section images, of the chitosan/PEG and chitosan sponges.  The smoother appearance of 
the chitosan and PEG blended sponges, as compared to the 1% chitosan sponges, may 
indicate the compatibility of two polymers in a blend.  The chitosan/PEG sponges’ 





 exhibited smooth and nonporous surfaces
6
 and smooth and homogenous cross 
sections
7
, respectively.   
In vitro degradation is one of the sponge material properties affected by the 
addition of PEG, molecular weight of PEG, and number of lyophilizations.  The addition 
of PEG 6000 to the chitosan sponges, as well as the use of only 1 lyophilization, caused 
the chitosan/PEG 6000 1 and 2 lyo and chitosan/PEG 8000 1 lyo sponges to degrade 
significantly in mass, with 1-75% sponge remaining over ten days, compared to 82.04-
97.46% and 99-100% sponge remaining in the chitosan/PEG 8000 2 lyo and control 
chitosan sponges.  As expected, the degradation of the blended chitosan/PEG sponges in 
this study is higher than the degradation that Tanuma et al. reported for PEG crosslinked 
chitosan films, 7% weight loss after 8 days of lysozyme mediated degradation.
23
  While 
molecular weight could not be directly measured through GPC methods, the sponges’ 
slight decrease in viscosity after ten days of degradation demonstrates there might be a 
slight decrease in sponge molecular weight after degradation; however, the viscosity of 
the blended sponges did not decrease as much as the 55% reduction in specific viscosity 
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of PEG grafted chitosan solutions in 7.5 mg/mL lysozyme reported in a previous study.
24
   
Although the chitosan/PEG 6000 and 8000 1 lyo sponges exhibited the lowest percent 
sponge remaining in the in vitro degradation study, the smoother surfaces of the blended 
sponges visualized by SEM, as compared to the chitosan sponge,  indicates that surface 
roughness may not be related to increased in vitro degradation. 
 Differences in amphotericin B elution were seen in the sponges upon adding PEG 
to the chitosan sponges and using only one lyophilization. The chitosan/PEG 6000 1 lyo 
sponge released 12.43 ± 3.81% of loaded amphotericin B after 72 hours, while the 
chitosan/PEG 6000 2 lyo sponge released 5.27 ± 3.55% of loaded amphotericin B over 
the same time frame.  While the chitosan/PEG 8000 1 lyo sponge only released 5.22 ± 
0.31% of loaded antifungal over 72 hours, the sponge released significantly more 
amphotericin B after one hour of elution than the other blended sponges.  Although the 
sponges are still retaining amphotericin B, all of the sponges released more antifungal in 
vitro than what has been previously reported for amphotericin B loaded bone cement, 
0.45 and 0.05% with and without a poragen
25
 or 0.03% release
26
 of loaded amphotericin 
B.  As expected, the percent cumulative release from the post-loaded chitosan/PEG 
blended sponges was less than the 60% amphotericin B release after 2 days from a 
preloaded Pluronic® based multi-block copolymer gel.
27
 
 Although the control chitosan sponges released more amphotericin B than some 
of the blended sponges with 7.68 ± 2.20% cumulative release, many of these antifungal 
eluates did not maintain sufficient activity against C. albicans.  Whereas, all the tested 
amphotericin B elution samples from the chitosan/PEG 6000 and 8000 1 lyo sponges and 
all but three elution samples from the chitosan/PEG 6000 2 lyo sponges remained active 
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against C. albicans.  The active amphotericin B eluates from the chitosan/PEG sponges 
are similar to previously reported active amphotericin B eluates from PMMA bone 
cement.
28
 The antifungal activity ZOI assay results in this current study provide an 
indication that the addition of PEG to the chitosan sponges is an improvement for 
antifungal elution and activity over the unblended chitosan sponges.  
 As expected, the chitosan/PEG blended sponges did not elicit any significant 
cytotoxic effects on normal human dermal fibroblasts.  Previous research has shown that 
adding PEG to chitosan films enhanced protein adsorption and cell adhesion, growth, and 
proliferation.
6
 The chitosan/PEG 8000 2 lyo sponge’s slight decrease in cell viability 
after one day of treatment indicates there may be more similarities between the 
chitosan/PEG 8000 2 lyo sponge and control chitosan sponge than the other blended 
sponges. The differences in cytocompatibility found over time for all sponges in this 
study are also similar to previous results reported for other chitosan applications.
3,29
  
 While adding PEG to the chitosan sponges resulted in increased in vitro 
degradation, the chitosan/PEG sponges did not exhibit increased in vivo degradation in 
the rat intramuscular model compared to the chitosan sponges.  However, similar to the in 
vitro degradation results, the chitosan/PEG 8000 1 lyo sponge demonstrated the lowest 
percent implant in the defect after ten days of implantation. Conversely, the increased in 
vivo degradation in the chitosan/PEG 6000 2 lyo sponge over the chitosan/6000 1 lyo 
sponge, whereas the opposite was shown in vitro, demonstrates the difficulty of 
translating from in vitro studies to in vivo. Although chitosan has been reported to be 
biodegradable and biocompatible, wide data variations exist in the literature; for example, 
one study reported chitosan to have minimal degradation after subcutaneous 
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implantation, while other researchers showed a chitosan wound dressing to have rapid 
degradation.
2,30,31
   There was also wide variation in results in this study which led to 
none of the blended sponges showing significant decreases, either in percent implant and 
percent fibrous tissue, from the control chitosan sponges.  
 Chitosan/PEG and chitosan sponges exhibited statistically similar inflammatory 
tissue responses, but the chitosan/PEG 6000 1 lyo sponge demonstrated increased 
inflammatory response after 4 days of implantation and slightly higher average tissue 
response after 10 days.  These results demonstrate that, in addition to reduced in vivo 
sponge degradation, the chitosan/PEG 6000 1 lyo sponge exhibits a more acute 
inflammatory response than the other two blended sponges; these findings have lead us to 
eliminate this blended sponge formulation from future research.  The average 
inflammatory response for the control chitosan sponges was also higher than all of the 
chitosan/PEG blended sponges after 10 days of implantation. However, the  
inflammatory responses from all of the sponges are still lower than the tissue response 
from the sutures and are similar to reported moderate inflammatory responses from 
chitosan coated titanium pins implanted in Sprague-Dawley rats.
32
   
 Although none of the sponges degraded within 28 days, all of the blended sponges 
appeared to be degrading over time and a few important differences can still be seen in 
the satellite animal data. After 28 days, the chitosan/PEG 6000 2 lyo sponge was 
surprisingly the most degraded of the sponge types, and was almost completely degraded.  
Even though these results are just in one animal for each sponge, the data still provides an 
indication of in vivo degradation trends.  
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 There has not been much research on local antifungal delivery systems, and many 
of the local delivery systems that exist release too little antifungal or are not designed to 
degrade.  In previous research, biocompatible polyethylene glycol (PEG) has been 
utilized to deliver the hydrophobic antifungal, amphotericin B.  Our results indicate that 
blending chitosan and PEG into sponges creates biocompatible and degradable sponges 
capable of point of care amphotericin B loading and in vitro release that perform better 
than our previously developed chitosan sponges. Future work is needed to extend the in 
vivo study to better define the time of in vivo degradation.  Other studies are also planned 
to study the loading and release of both antifungals and antibiotics, separately and 
combined, from the blended sponges so that the further development of the chitosan/PEG 
blended sponges may provide a truly customizable adjunctive therapy for bacterial and 
fungal contaminated musculoskeletal wounds.  
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CHARACTERIZATION OF LOCAL DELIVERY WITH AMPHOTERICIN B 
AND VANCOMYCIN FROM MODIFIED CHITOSAN SPONGES AND 
FUNCTIONAL BIOFILM PREVENTION EVALUATION 
Introduction 
Musculoskeletal trauma is one of the most prevalent types of injuries in the 
United States; more than three out of five of the unintentional injuries occurring annually 
in the U.S. are musculoskeletal injuries.
1,2
  Musculoskeletal extremity injuries are 
especially susceptible to multiple pathogenic, and sometimes drug resistant bacteria and 
fungi, such as methicillin resistant Staphylococcus aureus (MRSA), Pseudomonas 
aeruginosa, Acinetobacter baumannii, Escherichia coli, Aspergillus spp., and Candida 
albicans. 
2, 3
  These infection complications can  increase morbidity and/or mortality, as 
well as increase hospitalization costs and stays.
4
  Although bacteria typically cause the 
majority of musculoskeletal infections, invasive fungal infections (IFI) have recently 
caused significant problems for both the British and United States military; the U.S. 
reported that 78% of the IFI infected U.S. soldiers injured in Afghanistan from 2009 to 
2010 required lower limb amputations.
5
 However, these fungal infections are problematic 
for civilians as well as for the military; for example, invasive Candida infections are the 
third most common cause of hospital acquired infections.
6
  
In addition to the presence of multidrug resistant bacteria or fungi, the presence of 
necrotic tissue, debris, and fixation devices or implants creates a favorable environment 
for the development of biofilms and corresponding infection.
7
 According to an estimate 
by the CDC, approximately 65% of bacterial infections are associated with biofilms.
8
  In 
biofilms, the metabolic activity of the bacteria is reduced, resulting in less susceptibility 
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to antimicrobials and an increased minimal inhibitory concentration (MIC).
9
  
Additionally, the typical clinical presence of multiple bacterial and/ or fungal strains 
means that the traditional view of individual pathogen infections and single antimicrobial 
delivery may not be appropriate.
10
   
Because systemic antimicrobials cannot be administered at very high 
concentrations to fight localized bacteria, fungi, and/or  biofilms, local antibiotic delivery 
can be an effective route for treating wounds and minimizing infections, when used as an 
adjunctive therapy to systemic dosing.
11
  Additionally, local delivery systems often have 
the capability for the release of multiple antimicrobials for polymicrobial infection 
prevention.  While there are a large amount of local antibiotic delivery systems available, 
there have not many local antifungal delivery systems developed because of the 
problematic hydrophobicity of many antifungals.  Amphotericin B, a common clinically 





, a Pluronic® based gel
17
, and a composite of hydroxyapatite and 
chitosan
18,19
; however, all of these delivery systems were pre-loaded with the antifungal 
and the resulting data varies widely.  A local antifungal delivery system capable of 
expeditious point of care loading in the operating room would allow a clinician to tailor 
the antibiotic and/or antifungal choice and dosage for the needs of each patient.  
In previous studies, we developed a degradable chitosan sponge local antibiotic 
delivery system that is capable of tailored point of care antibiotic loading and release.
20,21
  
Additionally, these sponges can be loaded with multiple antibiotics and have released 
antibiotics at levels high enough to prevent S. aureus biofilm growth in vivo.
20,21
  The 
water soluble polymer polyethylene glycol (PEG) has also been utilized as a solvent for 
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cis-2-decenoic acid, a hydrophobic fatty acid, for incorporation into the same chitosan 
sponge delivery system.
22
 Polyethylene glycol exhibits low toxicity and immunogenicity 
and has been used in liposome or nanoparticle form as a solvent system for the systemic 
delivery of amphotericin B.
23-27
  Researchers have also modified chitosan hydrogels, 
fibers, and films with PEG, as well as blending or copolymerization.
23,28-30
   
Therefore, our research purpose was to determine if blending chitosan with PEG 
in sponge form would generate a local delivery system capable of releasing both 
antibiotic and antifungal for polymicrobial wound infection prevention. The first 
objective of this study was to evaluate the sponges’ swelling and in vitro amphotericin B 
and vancomycin release, both single and dual loaded, confirm antifungal and antibiotic 
activity, and determine the cytocompatibility of the eluates. The second objective of this 
research was to evaluate the capability of the chitosan/PEG blended sponges to prevent S. 
aureus biofilm growth in vivo in a preliminary infected catheter murine model.  
Methods 
Materials: Chitosan and polyethylene glycol (PEG) were purchased from Chitinor AS 
(Tromsway, Norway) and Sigma Aldrich (St. Louis, MO), respectively. Sodium 
deoxycholate solubilized amphotericin B and vancomycin were obtained from Amresco 
(Solon, OH) and Fisher Scientific (Pittsburg, PA), respectively. All other reagents and 
chemicals were of analytical grade and were purchased from Fisher Scientific.  
Sponge Fabrication: To fabricate blended chitosan and PEG sponges, 0.5% (w/v) of 
PEG, at 6,000 or 8,000 g/mol, was dissolved in a 1% (v/v) acetic acid solution.  After 
rapid PEG dissolution, 0.5% (w/v) of chitosan (250 kDa and 82.46 ± 1.679 degree of 
deacetylation) was added to the same solution.  Control chitosan sponges were made in 
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the same manner, but with 1% (w/v) chitosan in solution. Chitosan/PEG and chitosan 
solutions were mixed for approximately one hour and then poured into 42 mL aluminum 
pans at a volume of 25 mL.  Solutions were frozen for a minimum of one hour at -80°C, 
followed by lyophilization in a LabConco (Kansas City, MO) FreeZone 2.5 Liter 
Benchtop Freeze Dry System.   
After lyophilization, the control chitosan sponges and the chitosan/PEG sponges 
with 6,000 g/mol PEG were neutralized in either 0.6 or 0.25 M NaOH, respectively. 
Sponges were soaked in the base solutions for approximately 1-2 minutes and then 
washed in copious amounts of water until a neutral pH was reached.  Once neutralized, 
the chitosan and chitosan/PEG 6000 sponges were frozen and lyophilized again.  The 
chitosan/PEG sponges with 8,000 g/mol PEG were only lyophilized once and not 
neutralized.  All sponge groups were sterilized with low dose gamma irradiation at a 
dosage of 25-40 kGy. 
Swelling: Sponges were evaluated for their swelling ability by loading the pre-weighed 
sponges with 10 mL of 1 x phosphate buffered saline (PBS) via absorbance.  After 2 
minutes, the sponges were quickly blotted to remove excess surface water and then 
weighed immediately (n = 3). The swelling ability of the sponges was calculated using 
equation 1,  
                                                           Swelling Ratio 
 w
 d
                                                        (1) 
where Ww is the wet sponge weight and Wd is the original dry sponge weight.  
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In Vitro Antifungal and Antibiotic Elution: The in vitro local release of antifungals 
and/or antibiotics from the sponges was evaluated by loading the sponges with either 1 
mg/ml sodium deoxycholate solubilized amphotericin B, 4 mg/ml vancomycin, or a 
combined solution of 4 mg/ml and 1 mg/ml solution of vancomycin and sodium 
deoxycholate solubilized amphotericin B.  All antimicrobial solutions were created in 
sterile Ultrapure water, and the dual vancomycin and amphotericin B solution was made 
by creating separate antibiotic and antifungal solutions first and then combining the two 
solutions into one. All antimicrobial solutions were shaken immediately prior to use and 
10 mL of each solution was added to the sponges (n = 3).  After approximately one 
minute of absorbance, the antimicrobial solutions not absorbed by the sponges was 
removed and measured. Sponges were added to twenty mL of sterile 1x PBS in 125 mL 
Nalgene (Rochester, NY) containers and incubated at 37°C on a shaker.  Elution samples 
were removed after 1, 3, 6, 24, 48, and 72 hours in 1 mL aliquots and the PBS was 
completely refreshed.  
 The concentration of single loaded amphotericin B released from the sponges was 
measured via high pressure liquid chromatography (HPLC) with a ThermoScientific BDS 
Hypersil C18 column. Amphotericin B was measured at 407 nm in a mobile phase of 
acetonitrile, methanol, and 10 mM sodium phosphate monobasic (41:10:49).
31
  Both 
single and dual loaded vancomycin eluates were also measured with HPLC and the same 
column.  Vancomycin was measured at 235 nm in a mobile phase of 35% acetonitrile and 
65% buffer (0.08 M disodium phosphate and 0.013 M monosodium phosphate adjusted to 





 The concentrations of amphotericin B released from sponges loaded with both 
vancomycin and amphotericin B were also measured with ultraviolet visible (UV-Vis) 
spectroscopy since the antifungal was not accurately detected using the previously 
mentioned HPLC method.   According to an amphotericin B manufacturer
33
, the typical 
detection methods used for amphotericin B detection include microbial assays, HPLC, 
and UV-Vis; however, these methods have not been studied with simultaneous 
vancomycin elution. Because some of the dual elution samples exhibited precipitates, the 
eluates were added 1:1 to dimethylsulfoxide (DMSO) and well mixed.  The highly 
concentrated stock solution was diluted in DMSO multiple times.  Amphotericin B 
eluates from dual loaded sponges were read via absorbance at 389 nm in a Biotek 
(Winooski, VT) Synergy H1 plate reader.  Antifungal concentrations were calculated 
using an amphotericin B standard curve.  
In Vitro Antifungal Activity: To determine if the amphotericin B released from the 
single and dual loaded sponges maintained activity against a common fungi, a microbial 
zone of inhibition assay was conducted.  The amphotericin B eluates were lyophilized for 
one day, reconstituted in 5  μL of PBS, and used to inoculate blank discs.  Standard 
amphotericin B concentrations, ranging from   to 2.5 μg in  .25 μg increments, were also 
used to inoculate blank discs.  A 0.5 McFarland standard of Candida albicans was 
prepared in sterile PBS and used to streak a Mueller-Hinton agar plate in three different 
directions.  An inoculated disc was added to each plate and plates were incubated 
overnight at 37°C.  The zone of inhibition was measured for each amphotericin B 
standard and a standard curve was generated.  Zone of inhibition of amphotericin B 
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eluate samples were also measured and compared to the standard curve to determine 
sample concentration.  
In Vitro Antibiotic Activity: To determine if the vancomycin released from the single 
and dual loaded sponges maintained activity against bacteria, a bacterial turbidity assay 
was conducted following The Clinical and Laboratory Standards Institute standard M7-
A4, “Methods for Dilution Antimicrobial Susceptibility for Bacteria that Grow 
Aerobically”.
34
  Dilutions (1:10) of vancomycin eluates from single and dual loaded 
sponges were tested against S. aureus (UAMS-1). Vancomycin eluate samples were 
added in 2   μL increments to  .75 mL of sterile trypticase soy broth (TSB) and 5  μL of 
S. aureus inoculum with approximately 2x10
6
 colony forming units (CFU).  Sterile 1x 
PBS was also used as a positive control.  The inoculated elution samples were then 
mixed, incubated at 37°C overnight, mixed again and read via absorbance at 530 nm in a 
spectrophotometer.  
In Vitro Cytocompatibility: The in vitro cytocompatibility of the amphotericin B, 
vancomycin, and combination amphotericin B and vancomycin elution samples was 
tested on normal human dermal fibroblasts (NHDFs) purchased from Lonza 
(Walkersville, MD).  Cells (passages 9 through 12) were seeded at 2.5 x 10
4
 cells/ml in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with     fetal bovine 
serum (FBS), penicillin (100 units/mL), streptomycin (100 mg/mL), and amphotericin B 
( .25 μg/ml) on 48 well polystyrene tissue culture plates (TCP) under standard cell 
culture conditions (37°C and 5% CO2).  Elution samples were pre-warmed and diluted 
1:1 in fresh medium (n = 3), absent of additional antibiotics and antimycotics.  After cells 
reached near confluence, the cell culture medium was aspirated from the plates and 
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refreshed with the medium and eluate dilution samples.   Cells were incubated for one or 
three days before cytocompatibility was evaluated with the Cell Titer-Glo® 
Lumincescent Cell Viability assay, obtained from Promega (Madison, WI).  A standard 
dilution of known concentration of cells was also plated and assayed.  The luminescent 
signal, which corresponded to the amount of adenosine triphosphate and the number of 
viable cells based on the standard curve, was recorded at 590 nm with a BioTek Synergy 
H1 plate reader.  The number of viable cells was converted to cell viability percentage by 
normalization to the TCP controls in each respective plate.    
In Vivo Mouse Study: In vivo prevention of S. aureus biofilm growth by vancomycin 
loaded chitosan/PEG sponges was assessed in 20 NIH Swiss mice, following an 
established mouse model protocol.
35,36
 This in vivo study was approved by the 
institutional review board at the University of Arkansas for Medical Sciences (IACUC 
protocol #3461).  Mice were anesthestized with isoflurane in an environmental chamber 
and anesthesia was confirmed by lack of toe pinch reflex.  The mice were shaved and a 
0.3 cm incision was made in the skin on each flank.  A 1 cm section of 
polytetrafluoroethylene (PTFE) catheter was placed under the skin on each flank.  At the 
same time, the chitosan/PEG 6000, chitosan/PEG 8000, or control chitosan sponges were 
loaded with either 4 mg/ml vancomycin or 1x PBS solutions (4 animals and 8 catheters 
per group) and were placed adjacent to the catheters.  Incisions were closed with surgical 
glue and 1 cc of 10
4
 CFUs of S. aureus (UAMS-1 strain) was injected into the lumen of 
the catheter. After 48 hours post-surgery, mice were sacrificed and catheters were 
surgically removed from each flank and placed in a sterile saline solution.  The catheters 
were sonicated in PBS to remove adherent bacteria; the resulting bacteria aliquots were 
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then plated on tryptic soy agar and incubated at 37°C overnight in order to count the 
number of CFUs of S. aureus recovered from each catheter.  
Statistical Analysis 
 All data, except for the percent clearance of bacteria from the mouse model, is 
presented as mean ± standard deviation. One way ANOVA was used to analyze the 
swelling ratios of the sponges. Antifungal and antibiotic elution and antifungal activity 
was analyzed using three way Analysis of Variance (ANOVA) with Holm Sidak post hoc 
analysis.  Eluate cytocompatibility data was analyzed with three way ANOVA with Holm 
Sidak post hoc analysis compared to the controls. Colony forming unit data from the in 
vivo mouse model was analyzed with the nonparametric Kruskal-Wallis one way 
ANOVA on ranks with Tukey post hoc analysis.  Statistical significance level was set at 
α    . 5. 
Results 
Results from the swelling analysis of the blended chitosan/PEG and control 
chitosan sponges are provided in Table 1, along with critical details about each sponge 
formulation.  As expected, the blended sponge with 1 lyophilization exhibited a 
significantly higher average swelling ratio than the chitosan sponge.  The chitosan/PEG 
6000 sponge with 2 lyophilizations also exhibited a higher swelling ratio than the 











Table 1. Formulation variables and swelling ratios (n = 3) of blended chitosan/PEG and 
chitosan sponges, where * indicates p = 0.033 versus each other. 







Chitosan/PEG 6000 6000 2 0.25 M 19.82 ± 5.72 
Chitosan/PEG 8000 8000 1 N/A 23.21 ± 0.91* 
Chitosan N/A 2 0.6 M 12.94 ± 1.63* 
  
 
The in vitro amphotericin B (the sodium deoxycholate form) release profiles of 
chitosan/PEG and chitosan sponges, loaded with amphotericin B alone or in combination 
with vancomycin, are shown in Figure 1.  All sponges released amphotericin B, alone and 
in combination with the antibiotic, well above the amphotericin B minimum inhibitory 
concentration of Candida albicans over the 72 hour elution. The dual loaded sponges also 
released more amphotericin B than the single loaded sponges, especially after one hour of 
elution. Overall significant differences could be seen in the antifungal release between 








Figure 1. Sodium deoxycholate solubilized amphotericin B released in vitro in µg/ml 
(mean ± standard deviation) from single loaded and dual loaded (with vancomycin) 
sponges over time (n   3), where * indicates p <  . 5 pairwise overall, and † represents p 




Unlike the antifungal elution, vancomycin release from single and dual loaded 






Figure 2. (A) Vancomycin released in vitro in µg/ml (mean ± standard deviation) from 
single loaded and dual loaded (with amphotericin B) sponges over time (n = 3), where at 
each respective time point, * indicates p < 0.001 versus other loading condition within 
sponge group, † represents p <  . 5 versus all other sponges, and ** denotes p < 0.001 






All sponges released vancomycin at levels above the S. aureus MIC through 24 
hours, but only the dual loaded chitosan/PEG 8000 and chitosan sponges released 
vancomycin above the MIC through 72 hours of elution.  The chitosan/PEG 8000 single 
loaded sponge also released significantly more vancomycin than the other dual loaded 
sponges after one hour of elution and than all other sponges after three hours.  
Additionally, the opposite behavior to the amphotericin B release appeared in the 
sponges’ vancomycin release; instead of the dual loaded sponges releasing more 
antibiotic, the single loaded sponges release more vancomycin than the dual loaded.  
Antifungal activity zone of inhibition assay results, reported as amphotericin B 
concentration in μg/ml, are shown in Figure 3.  All selected amphotericin B eluates 
remained active against C. albicans at all time points.  After three hours of elution, the 
same trend was found as in the antifungal elution data, where the dual loaded sponges 
released more active amphotericin B than the single loaded sponges.  However, the 
chitosan/PEG 6000 dual loaded sponge did not exhibit higher average levels of active 







Figure 3. Results from antifungal activity zone of inhibition assay using selected 
amphotericin B eluted from chitosan/PEG and chitosan sponges, where * indicates p = 




 The activity of vancomycin released from single and dual loaded chitosan/PEG 
and chitosan sponges against Staphylococcus aureus is reported in Table 2.   All sponges 
released vancomycin active against the bacteria over six hours of elution, and the dual 
loaded chitosan sponges still inhibited bacterial growth through 24 hours.  As previously 
reported in Figure 2, the dual loaded chitosan sponges released more amphotericin B at 








Table 2. Activity of 1:10 dilutions of vancomycin released (both single loaded and 
dual loaded with amphotericin B) from blended chitosan/PEG and control chitosan 
sponges against S. aureus 
  Hours of Elution 
Loading Sponge 1 3 6 24 48 72 
Single Chitosan/PEG 6000 2 lyo - - - + + + 
Single Chitosan/PEG 8000 1 lyo - - - + + + 
Single 1% Chitosan - - - + + + 
Dual Chitosan/PEG 6000 2 lyo - - - + + + 
Dual Chitosan/PEG 8000 1 lyo - - - + + + 
Dual 1% Chitosan - - - - + + 




 As seen in Figures 4A-C, the one hour amphotericin B elution samples from 
single loaded chitosan/PEG sponges caused significant decreases in cytocompatibility 
from the control tissue culture plastic plate after one and three days of treatment.  
However, these same sponge eluate samples exhibited a rebound effect on the viability 
after one hour or three hours of elution for chitosan/PEG 6000 and 8000 sponges, 
respectively.  An increase in cell viability occurred from one to three days of treatment 







Figure 4. Cytocompatibility (mean ± standard deviation) of single loaded amphotericin B 
eluates (n = 3) from the (A) chitosan/PEG 6000 sponge, (B) chitosan/PEG 8000 sponge, 
and (C) control chitosan sponge, to normal human dermal fibroblasts after one and three 
days. Cells was analyzed using Cell Titer-Glo® luminescent assay and resulting cell 
numbers were converted to percent cell viability by normalization to tissue culture plastic 




 As expected, vancomycin eluted from single loaded chitosan/PEG and chitosan 
sponges exhibited higher cell viability than the released amphotericin B (Figures 5A-C).  
However, while none of the elution samples exhibited significantly lower cell viability 
than the TCP controls after one day of treatment, all elution samples for each sponge 








Figure 5. Cytocompatibility (mean ± standard deviation) of single loaded vancomycin 
eluates (n = 3) from the (A) chitosan/PEG 6000 sponge, (B) chitosan/PEG 8000 sponge, 
and (C) control chitosan sponge, to normal human dermal fibroblasts after one and three 
days. Cells was analyzed using Cell Titer-Glo® luminescent assay and resulting cell 
numbers were converted to percent cell viability by normalization to tissue culture plastic 




 Combination vancomycin and amphotericin B eluted from all dual loaded sponge 
types caused high decreases in cell viability after one day of treatment (Figures 6A-C), 
but no statistical difference was found over time for the elution time points (p = 0.279).  
However, these same eluates exhibited higher cell viability after three days of treatment 
from six to 72 hours of elution from their respective one treatment day numbers. The one 
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and three hour elution samples from the chitosan/PEG 6000, 8000, and chitosan sponges 
exhibited significantly lower cell viability than the controls, and the 72 hour elution 
sample from chitosan/PEG 8000 sponge also cause a significant decrease in cell viability 





Figure 6. Cytocompatibility (mean ± standard deviation) of dual loaded vancomycin and 
amphotericin B eluates (n = 3) from the (A) chitosan/PEG 6000 sponge, (B) 
chitosan/PEG 8000 sponge, and (C) control chitosan sponge, to normal human dermal 
fibroblasts after one and three days. Cells was analyzed using Cell Titer-Glo® 
luminescent assay and resulting cell numbers were converted to percent cell viability by 







 Results from the in vivo S. aureus biofilm prevention mouse model are provided 
in Figures 7A and B.  As seen in Figure 7A, the vancomycin loaded chitosan/PEG 6000 
sponge resulted in 100% bacteria clearance from the catheters.  Six of the eight catheters 
used with the vancomycin loaded chitosan/PEG 8000 sponges were cleared, while only 
50% of the catheters treated with the vancomycin loaded chitosan sponges were cleared.  
Additionally, as revealed by Figure 7B, the average colony forming units on the 
colonized catheters from the vancomycin loaded chitosan/PEG 8000 and chitosan sponge 
treatments were significantly lower than the CFUs from the PBS loaded chitosan/PEG 














Figure 8. (A)  Percentage of catheters cleared of S. aureus and (B) the average colony 
forming units (CFUs) per catheter for catheters retrieved from mice treated with 
chitosan/PEG 6000, chitosan/PEG 8000, and chitosan sponges (four animals and eight 
catheters). Sponges were loaded with either PBS or 4 mg/ml of vancomycin (Vanc) * 







 Polymicrobial musculoskeletal infections, especially from invasive bacteria , 
fungi or biofilm pathogens, are challenging complications that often increase patient 
morbidity, mortality, and hospitalization costs.
37
 The clinical need for degradable local 
antimicrobial delivery systems to fight localized bacteria, fungi, and/or biofilms with 
patient tailored antimicrobial point of care loading has resulted in the previous 
development of a chitosan sponge local delivery system.
11,20,21
   Our research was 
designed to determine if the blending of these chitosan sponges with polyethylene glycol 
would result in local drug delivery systems capable of antifungal and antibiotic release 
for the prevention of polymicrobial wound infections.   
 After previous sponge formulation and material characterization, the selected 
chitosan/PEG sponges were evaluated for their swelling, in vitro amphotericin B and 
vancomycin release, both alone and in combination, as well as activity and 
cytocompatibility of the resulting antimicrobial eluates.
38
  The chitosan/PEG 6000 
sponge formulations exhibited higher in vitro amphotericin B release when loaded with 
vancomycin, while the chitosan/PEG 8000 sponge exhibited the highest swelling and 
released more vancomycin in vitro, both alone and in combination with the antifungal.  
Antibiotic eluates from the blended sponges did not exhibit differences in activity against 
S. aureus and all the amphotericin B elution samples tested remained active against C. 
albicans. Antifungal eluates from blended sponges, both alone and in combination with 
vancomycin, caused significant decreases in cell viability after one and three hours of 
elution, compared to controls.  However, cells recovered as the time of amphotericin B 
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elution increased, when the amphotericin B concentrations were reduced in the samples. 
Interestingly, vancomycin elution from the blended chitosan sponges exhibited opposite 
behavior in vivo to in vitro vancomycin release. In the mice, the vancomycin loaded 
chitosan/PEG 6000 sponge cleared 25% and 50% more of the bacteria from the catheters 
than the vancomycin loaded chitosan/PEG 8000 and chitosan sponge, respectively.   
Comparing the blended chitosan/PEG sponges to the sparse previous literature on 
local antifungal delivery, there are some similarities and differences to published research 
on local antifungal delivery systems.
12,13,17,39
 While the blended sponges in this study still 
retainined amphotericin B, both the chitosan/PEG 6000 and 8000 sponges released more 
antifungal in vitro in comparison to previously reports for amphotericin B loaded PMMA 
bone cement.  Kweon et al.
13
 and Goss et al.
12
 have reported bone cement to release 0.45 
and 0.05%, with and without a poragen, or 0.03% of loaded amphotericin B, respectively.  
However, the chitosan/PEG sponges released less antifungal than the 60% cumulative 
amphotericin B released after two days from a preloaded Pluronic® based copolymer 
gel.
17
 Additionally, the amphotericin B eluates from the sponges in this study are similar 
to the reported active amphotericin B eluted from PMMA bone cement.
39
  While 
antifungal released from the blended sponges reduced cell viability after one hour of 
elution, previous research has confirmed amphotericin B’s negative effects on cells, when 
exposed to high concentrations.
40
  Harmsen and researchers have studied amphotericin B 
at typical locally delivered concentrations and found amphotericin B at     μg/ml caused 
fibroblast death after 5 hours, while 5 and    μg/ml caused abnormal cell morphology 





The in vitro local vancomycin release from the blended sponges can also be 
compared to previous studies on antibiotic loaded chitosan sponges.
20,21,41
 Vancomycin 
release after one hour of elution, from single or dual loaded sponges, was 23-52% and 
12-59% higher from the chitosan/PEG sponges than previously studied vancomycin 
loaded crosslinked chitosan sponges.
41
 However, unlike the blended sponges, these 
previously studied crosslinked sponges released vancomycin at levels above the S. aureus 
MIC throughout the entire 72 hours of elution.
41
  The chitosan/PEG 8000 sponge, loaded 
with vancomycin only, initially released more vancomycin in vitro than previously 
reported for chitosan sponges made with lactic and acetic acid and loaded with 5 mg/ml 
vancomycin; however, the blended sponge did not release high enough levels of 
vancomycin throughout the entire elution study to inhibit S. aureus growth as long as 
described in the previous study.
20
  
 Limitations of this study include the challenging in vitro measurement of 
amphotericin B concentration when released simultaneously with vancomycin and the 
lack of direct comparison in the antifungal and antibiotic activity assays due to the 
different dilutions utilized in the studies.  However, this study is one of the few published 
studies on the simultaneous in vitro loading and release of amphotericin B and a 
representative antibiotic, vancomycin.  Additionally, the small number of animals and 
antibiotic concentrations studied in the pilot in vivo study should be increased in future 
animal studies.  However, the initial results of the preliminary in vivo model provide a 
sufficient trend of the in vivo behavior of the blended chitosan sponges to prevent biofilm 
formation. Although additional work is needed to evaluate in vivo release of amphotericin 
B, the blended chitosan and polyethylene glycol sponges may provide a way to locally 
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deliver clinician selected antifungals and/or antibiotics for use as an adjunctive therapy 
for the prevention of polymicrobial musculoskeletal wound infections.  
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 The results presented in this dissertation indicate that the chitosan sponge can be 
modified, either through buffering with sodium acetate or blending with polyethylene 
glycol (PEG), to create local drug delivery systems with different in vitro material 
properties and in vivo functionality for wound infection prevention.  Chapter 2 
demonstrated the capability to modify the properties of the chitosan sponge through a 
buffering procedure to increase degradation and still remain biocompatible.  Additionally, 
the results indicate that one can adapt the characteristics of the sponge based on the 
intended application, for example, a short or long length of degradation.   
 The polyethylene glycol and chitosan blended sponges developed in Chapters 3 
and 4 also confirmed chitosan’s modification potential, but through blending with an 
additional polymer instead of a buffer.  By adding PEG to the chitosan sponges, an 
increase in in vitro water insoluble amphotericin B release was seen, as well as increased 
activity of the antifungal eluates compared to the control unmodified chitosan sponges.  
Similar to the buffered sponges from Chapter 2, the chitosan/PEG sponges also exhibited 
increased in vitro degradation from the original chitosan sponges and remained 
cytocompatible (Chapter 3).  Specifically, the chitosan/PEG 8000 1 lyo sponge 
demonstrated increased in vitro degradation from both buffered sponges, and the 
chitosan/PEG 6000 1 lyo sponge exhibited increased degradation from the pH 5.6 
buffered sponge.  Modifying the chitosan sponge with PEG also resulted in similar cell 
viability results to the buffered chitosan sponges.  In the in vivo intramuscular rat model, 
the chitosan/PEG blended sponges revealed higher percentage of implant area in the 
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defect area than the buffered sponges.  However, the PEG modified sponges exhibited 
less fibrous tissue overall and a decreased average graded inflammatory response after 
ten days of implantation than the buffered chitosan sponges. Both the buffered and PEG 
modified chitosan sponges exhibited reduced in vivo degradation compared to their in 
vitro degradation analyses.  
 Chapter 4 described an in vitro and in vivo evaluation of the functionality of the 
chitosan/PEG sponges for local antifungal and antibiotic release and infection prevention.  
The chitosan/PEG sponges with a PEG molecular weight of 6,000 g/mol and two 
lyophilizations exhibited a slight increase in in vitro water soluble amphotericin B release 
(single loaded) after one hour of elution, but the chitosan/PEG 8000 sponge with one 
lyophilization demonstrated increased in vitro vancomycin elution from either single or 
dual loaded sponges, compared to the other sponge groups. However, the opposite 
behavior was seen in the pilot in vivo Staphylococcus aureus biofilm infection prevention 
mouse model, where the vancomycin loaded chitosan/PEG 6000 and 8000 sponges 
cleared 100% and 75% of the bacteria from the implanted catheters, respectively.  Both 
antibiotic loaded PEG modified sponges exhibited improvements in biofilm prevention 
over the control unmodified chitosan sponges, loaded with vancomycin or PBS.  These in 
vitro and in vivo results indicate the potential use of the antifungal and/or antibiotic 
loaded chitosan/PEG sponge local delivery system for use as an adjunctive therapy to 
prevent bacterial and fungal wound infections.  However, as recommended in Chapter 6, 
additional research is needed to confirm in vivo chitosan/PEG sponge functionality for 
prevention of fungal infections.  
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 In conclusion, these results provide strong support of the stated hypothesis: that 
modified chitosan sponges, with a buffer or polyethylene glycol, will function as 
degradable local antimicrobial delivery systems for use as an adjunctive therapy to 
prevent infection establishment in musculoskeletal wounds.  The PEG modified chitosan 
sponges were specifically shown to function as a local delivery system for both 
hydrophilic antibiotics and hydrophobic antifungals, loaded alone or in combination.  
While additional work is needed to confirm the in vivo degradation of both types of 
modified sponges, the significant in vitro degradation indicates the potential for eventual 
degradation.  With additional research, both of these modified chitosan sponges could 
meet the clinical need of reliable, low-cost polymicrobial infection prevention that can be 
used as an adjunctive topical therapy to surgical debridement and irrigation and systemic 















RECOMMENDATIONS FOR FUTURE WORK 
  Additional research evaluations should be conducted on the chitosan/PEG sponge 
in order to develop a more thorough understanding of the sponge’s properties and its 
functionality for local antifungal delivery and infection prevention. More in vitro elution 
studies and activity research with other antifungals, such as voriconazole, or other 
hydrophobic compounds could extend the possible applications of the modified chitosan 
sponge.  The chitosan/PEG sponges should also be evaluated for in vitro antibiotic 
delivery with antibiotics other than vancomycin and tested against bacteria other than 
Staphylococcus aureus.  
In order to increase degradation, PEG with a lower molecular weight could be 
blended with chitosan because previous research has shown a link between molecular 
weight and degradation.
44,59
 Additionally, an extended in vivo degradation study for both 
the PEG modified and buffered chitosan sponges would provide a more accurate length 
of time for complete degradation.  In order to assess the in vivo functionality of the 
modified sponges for fungal infection prevention, it is also recommended that 
amphotericin B loaded chitosan/PEG sponges be evaluated in an in vivo fungal infection 
model.  Finally, both the buffered and chitosan/PEG sponges should be studied in an in 
vivo large animal model, with traumatic musculoskeletal wounds more applicable to 
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PRELIMINARY FORMULATION RESEARCH 
 Prior to the resulting chitosan and polyethylene glycol sponge formulations 
described in Chapters 3 and 4 of this dissertation, extensive formulation research was 
performed in order to reach the final sponge formulations.  The variables tested and 
selected for the final sponge formulations, along with the reasons for selection are 




Table 1. Chitosan and polyethylene glycol sponge formulation variables tested 
Variable  Variable Tested Reason for Selection 
Weight percentage 1% or 2% Degradation 
Chitosan: PEG Ratio 1:1, 2:1, or 4:1 Elution & degradation 
Chitosan Supplier Primex or Chinitor AS Supplier change 
DDA 61%, 71%, or 82% Supplier change 
PEG MW (g/mol) 6,000, 8,000, or 10,000 Degradation 
NaOH concentration (M) 0.25, 0.6, or 1 Degradation & swelling 
Acid type 1% Lactic/acetic acid (75:25) 
or 1% acetic acid 
Degradation & sponge 
flexibility 
Freezing temperature -20°C or -80°C Freezer space, no 
difference otherwise 
Order of addition Chitosan first or PEG first Easier to dissolve 
chitosan 
Number of lyophilizations 1 or 2 Degradation 




 In the first round of sponge formulations, 1:1, 2:1, and 4:1 Chitosan: PEG sponges 
were prepared in 1% acetic acid.  Chitosan with a DDA of 71% from Primex and PEG 
with a molecular weight of 8,000 g/mol were used for each sponge type.  All of the 
sponges were lyophilized twice and neutralized in 1 M NaOH.  The in vitro lysozyme 
based degradation of the sponges was analyzed, as well as the in vitro water insoluble 
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amphotericin B elution; both experiments were previously described in Chapter 3.  The 
percentage of sponge remaining after two or four days of in vitro degradation is shown in 
Figure 1.  None of the chitosan/PEG blended sponges exhibited any significant 





Figure 1. Mean in vitro lysozyme mediated degradation of first chitosan/PEG sponge 




The elution profile of water insoluble amphotericin B from the 1:1, 2:1, and 4:1 
chitosan/PEG sponges is provided in Figure 2. Once again, not many significant 
differences can be seen between the sponge groups, except that the 2:1 chitosan/PEG 
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sponge released slightly more amphotericin B after one and three hours than the other 
formulations. Because not many differences in degradation or antifungal elution were 
revealed between the three original sponge formulations, the 1:1 chitosan/PEG sponge 
was selected due to the belief that this sponge formulation would exhibit increased 





Figure 2. Mean amphotericin B (water insoluble) elution (±standard deviation) from first 




In the second round of formulation research, 1:1 chitosan/PEG sponges were 
developed in 1% acetic or blended (75:25 lactic: acetic) acid.  Chitosan with 61% or 71% 
DDA and PEG with a molecular weight of 6,000 or 8,000 g/mol were utilized to make 
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the sponges.  One sponge was made by dissolving chitosan in the acid first, followed by 
PEG.  The remaining sponges were fabricated by dissolving PEG first.  Sponges were 
neutralized in 0.25, 0.6, or 1 M NaOH, frozen at -80°C, and lyophilized twice.  The 
swelling ability of the sponges in water was characterized, following the procedure 
described in Chapter 4 (Figure 3).  The chitosan/PEG sponge neutralized in 0.25 M 
NaOH exhibited the highest swelling ratio compared to the other sponges.  These results 











In the third round of formulation research, 1:1 chitosan/PEG sponges were fabricated 
in 1% acetic or blended (75:25 lactic: acetic) acid.  Sponges were prepared with either 
61% or 71% DDA chitosan and 6,000, 8,000, or 10,000 g/mol PEG.  All sponges were 
neutralized in 0.25 M NaOH and lyophilized twice.  Another in vitro degradation study 
was conducted with these chitosan/PEG sponge formulations, and these results are 






Figure 4. In vitro degradation of second round of chitosan/PEG sponge formulations after 
4 days in 1 mg/ml lysozyme solution, all sponges were made with 1% blended acid 






 As shown in the degradation results, the sponge formulated with 1% acetic acid 
exhibited significant increased degradation than the sponges formulated with 1% blended 
acid.  Thus, acetic acid was selected as the sponge solvent for future chitosan/PEG 
sponge formulation.  
After the third round of sponge formulations, our laboratory changed chitosan 
suppliers from Primex to Chitinor AS.  Whereas Primex produced 61% and 71% DDA 
chitosan, Chitinor AS produced chitosan with an average 82% DDA.  This specific 
chitosan was selected because our industrial research partner, Bionova Medical, used this 





ADDITIONAL CYTOCOMPATIBILITY EVALUATIONS 
Objective 
 In vitro cytocompatibility of materials is a useful tool to screen potential 
candidates for eventual in vivo implantation. Cell viability results from a direct contact 
study with the chitosan/PEG sponges and the antimicrobial sponge eluates are reported in 
Chapters 3 and 4, respectively. However, additional microscopic evaluation and live/dead 
staining of the normal human dermal fibroblasts (NHDFs) in direct contact with the 
chitosan/PEG sponges was conducted in order to identify cellular morphology.  
Additionally, cytocompatibility of cells in contact with standard solutions of 
amphotericin B and vancomycin, both alone and in combination, was assessed to identify 
cytotoxic concentrations of the antimicrobials, independent of the antimicrobial elution 
from the sponges.   The stock antibiotic and antifungal solutions used to load the 
chitosan/PEG sponges in Chapter 3 were also tested for cytocompatibility.  
Live/Dead Staining 
 Normal human dermal fibroblasts were seeded in 12 well tissue culture plastic 
plates at 2.89 x 10
4
 cells/ml in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and penicillin (100 units/mL), 
streptomycin (100 mg/mL), and amphotericin B (0.25 µg/mL) under standard cell culture 
conditions (37°C and 5% CO2 atmosphere).  Cells were allowed to proliferate to near 
confluence, after which cell culture medium was aspirated and refreshed with 1 mL of 
fresh medium. Chitosan, chitosan/PEG, and control polyurethane sponges were soaked in 
pre-warmed, sterile 1 x PBS for approximately 20 minutes.  A single 8 mm diameter test 
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specimen (n = 5) was then gently placed in a well in direct contact with the cell 
monolayer.  Cultures were incubated for one day before biocompatibility and cellular 
morphology was assessed with the LIVE/DEAD® Viability/Cytotoxicity kit, obtained 
from Molecular Probes.  Cell culture media was removed and replaced with Live/Dead 
solution, which consisted of 35 μl of 2 mM ethidium homodimer-1 and 25 μL of 4 mM 
calcein in 1 x PBS.  Plates were incubated at room temperature before images of the 
stained cells were taken with an EVOS microscope at 4 x magnification. Representative 
images of stained cells after one day of direct contact with the sponges are shown in 





Figure 1.  Images of normal human dermal fibroblasts stained with calcein (live cells) 
and ethidium homodimer-1 (dead cells) after one day of direct contact with the 1% 
chitosan sponge, chit/PEG 6000 1 lyo, chit/PEG 6000 2 lyo, chit/PEG 8000 1 lyo, 






 All of the sponges exhibited good cell viability, with hardly any visible dead cells 
present.  However, there are a few differences in cellular morphology.  While the 
chitosan/PEG 6000 1 lyo, chitosan/PEG 6000 2 lyo, and chitosan/PEG 8000 1 lyo 
sponges all exhibited similar effects on cell morphology as the polyurethane sponges, the 
1% chitosan and chitosan/PEG 8000 2 lyo sponges caused slight cellular malformation.  
The cells exposed to these two sponge groups exhibited reduced elongation.  This effect 
on in vitro cellular morphology led to the decision to exclude the chitosan/PEG 8000 2 
lyo sponge from future experimental analysis.  
Antimicrobial Solution Cytocompatibility 
 To evaluate the effects of both stock and standard solutions of amphotericin B and 
vancomycin, both alone and in combination, normal human dermal fibroblasts were 
seeded at 2.5 x 10
4
 cells/ml in 48 well plates in the same cell culture conditions described 
in Chapter 4. Standard concentrations of amphotericin B and vancomycin at 1000, 100, 
10, and 1 μg/ml and 4000, 400, 40, and 4 μg/ml, respectively,were prepared in 1:1 
dilutions in sterile pre-warmed media.  Standard concentrations of vancomycin and 
amphotericin B in combination were also prepared at a total antimicrobial concentration 
of 5000, 500, 50, and 5 μg/ml (4000, 400, 40, and 4 μg/ml and 1000, 100, 10, and 1 
μg/ml of vancomycin and amphotericin B combined).  The original stock loading 
solutions of amphotericin B and vancomycin, both alone and in combination, from 
Chapter 4 were also diluted in media, along with a PBS control.  
 After cells reached near confluence, culture media was removed and replaced 
with the antimicrobial solution dilutions.  Cells were incubated for one or three days, 
after which cell viability was assessed with the Cell Titer-Glo® Luminescent Cell 
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Viability assay, purchased from Promega.  The luminescent signal, which corresponded 
to the amount of adenosine triphosphate and the number of viable cells through a 
standard dilution of known concentrations of cells, was recorded at 590 nm using a 
BioTek Synergy H1 plate reader. Cell concentrations were converted to percentage of 
cell viability by comparison to tissue culture plastic controls, which were represented as 
100% cell viability. 
Results from the cytocompatibility study with standard antimicrobial solutions are 
provided in Figure 2, while the cytocompatibility data from stock antimicrobial solutions 
used to load chitosan and chitosan/PEG sponges is shown in Figure 3.  As expected, a 
large difference in cell viability exists between the vancomycin and amphotericin B 
solutions, both in the standards and stock solutions.  Amphotericin B is known to be toxic 
at high levels; one previous study has found that concentrations of 100 μg/ml caused cell 
death after five hours.
60
 However, the modified sponges studied in this work did not 
release amphotericin B at levels high enough to cause severe cell death, as seen in the 
1000 and 100 μg/ml samples in Figure 2. Not surprisingly, the dual vancomycin and 
amphotericin B solutions also exhibited similar cytotoxicity to amphotericin B alone; the 
dual solutions contained the same amount of amphotericin B as the single solutions. 
Interestingly, the vancomycin solutions exhibited larger decreases in cell viability from 
one to three days of treatment than the amphotericin B and dual antimicrobial solutions.  
However, the PBS group also exhibited this decreased cell viability, which indicates this 
effect might be simply due to the dilution of media over three days.  
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 Figure 2. Cytocompatibility (mean ± standard deviation) of (A) standard vancomycin 
solutions (n = 3), (B) standard amphotericin B solutions (n = 3), and (C) standard 
vancomycin and amphotericin B combination solutions to normal human dermal 
fibroblasts after one and three days. Cells were analyzed using Cell Titer-Glo® 
luminescent assay and resulting cell numbers were converted to percent cell viability by 
normalization to tissue culture plastic (TCP) controls. (* indicates p<0.05 versus all, ** 




Figure 3. Cytocompatibility (mean ± standard deviation) of normal human dermal 
fibroblasts after one and three days of treatment of stock amphotericin B, vancomycin, 
and combination vancomycin and amphotericin B solutions (n = 3) used to load 
chitosan/PEG and chitosan sponges in in vitro antimicrobial elutions. (* indicates p<0.05 








EVALUATION OF TWO SOURCES OF CALCIUM SULFATE FOR A LOCAL 
DRUG DELIVERY SYSTEM: A PILOT STUDY 
Introduction  
Wound infection and osteomyelitis can be challenging to treat especially with 
complex musculoskeletal trauma in civilian and military populations, and can result in 
multiple surgeries and increased costs [1,2]. Local drug delivery is emerging as a useful 
route for treating acute and chronic wound infections. Because drugs are delivered to the 
entire body in systemic drug delivery, toxicity issues can often arise as well as antibiotic 
resistance [3]. Organisms that are typically antibiotic-resistant in systemic delivery can be 
more susceptible to the higher levels of antibiotics provided through local delivery [3]. 
Additionally, the drug can take a longer time to reach the wound when delivered 
systemically and some avascular areas of the body are unreachable [3]. In local drug 
delivery, the wound area is targeted and the drug does not substantially affect other parts 
of the body; however, local drug delivery systems do not completely eliminate toxicity 
issues and antibiotic resistance.  The ideal local drug delivery system would be 
implanted, deliver antibiotics at appropriate levels and lengths of time based on 
application, and then degrade so there would be no need for a second surgical procedure 
for removal [3].  
Another difficult challenge with complex musculoskeletal trauma is resistant 
bacteria. Wound infection can be complicated by wound contamination with antibiotic-
resistant bacteria, which can increase treatment difficulty. Methicillin-resistant 
Staphylococcus aureus (MRSA) is a serious concern in modern medicine and serves as a 
problem in wound treatment. Antibiotic-resistant bacteria have created a need for newer 
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antibiotics as an adjunct for past antibiotic selections such as vancomycin. Daptomycin is 
a semisynthetic antibiotic with activity against Gram-positive bacteria and has 
demonstrated activity against MRSA [4,5]. Daptomycin has been previously researched 
combined with a calcium sulfate (CaSO4) carrier, and daptomycin reportedly elutes 
similarly to tobramycin in vitro [6,7].   However, like with many antibiotics used for 
infected wound treatment, bacterial resistance to daptomycin has been recently reported 
[8]. 
CaSO4 has been previously used as a bone void filler and in bone defects is 
absorbed by the surrounding tissue, possibly accelerating bone healing [9]. CaSO4 is a 
biocompatible, biodegradable material with osteoconductive properties that exhibits a 
bolus, or burst, release followed by an extended drug release from several hours to weeks 
depending on the formulation [10,11]. CaSO4 has been used to deliver vancomycin, 
gentamycin, tobramycin, lincomycin, cefazolin, teicoplanin, and fucidin [12-14]. 
Another, and the most common, material used for local drug delivery is 
polymethylmethacrylate (PMMA) [15]. Although PMMA implants are not 
biodegradable, their removal may be necessary at times for planned staged reconstruction 
or late bead failure [16]. Because CaSO4 degrades over time, the need for surgical 
removal is eliminated. Clinical studies and animal models suggest using antibiotic-loaded 
calcium sulfate pellets minimizes infection [17-19]. Although there are numerous 
potential applications in which calcium sulfate is beneficial as a drug delivery material, 
the mechanical properties of calcium sulfate do make it insufficient for load-bearing 
applications [20]. Recently, two sources of CaSO4 that are commercially available have 
been studied for their use in local antibiotic delivery. To make pellets with daptomycin 
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from one type of CaSO4 (hemihydrate synthesized from naturally occurring USP grade 
gypsum), a catalyst, K2SO4, is required [7].  It has been proposed the K2SO4 catalyst 
would not be necessary to form pellets from a synthetic CaSO4.  A comparison of 
antibiotic elution, pellet degradation, and the need for a catalyst of these two CaSO4 
sources has not been investigated. 
We asked the following questions: (1a), is the pellet degradation and (1b), 
daptomycin elution profile different for two different forms of CaSO4, naturally sourced 
from gypsum and synthetic; (2) does the presence of a catalyst, potassium sulfate 
(K2SO4), affect the degradation and the daptomycin elution profile of the CaSO4 pellets 
manufactured from two different sources; and (3) is the daptomycin released from both 
sources of CaSO4 pellets active against bacteria associated with osteomyelitis, 
specifically S. aureus?  
Materials and Methods 
To determine whether the pellet degradation, daptomycin elution profile, and 
activity against S. aureus were affected by the type of CaSO4 or the presence of a 
catalyst, we prepared the CaSO4 pellets in three groups, synthetic CaSO4 and 3% K2SO4, 
synthetic CaSO4 and 0% K2SO4, and naturally sourced CaSO4 with 3% K2SO4 as seen in 
Figure 1.  Four of each type of pellet was placed in each vial and there were four total 
replications, or vials, for each group in each test. Each pellet group was tested in an 
elution study, degradation study, and activity testing with the dependent variables being 




Figure 1. A flowchart demonstrates the study design with the three test groups and the 





pellets with 0% 
K2SO4  
Synthetic CaSO4 
pellets with 3% 
K2SO4 
Sourced CaSO4 
pellets with 3% 
K2SO4 
Elution tests performed with three CaSO4  
pellet groups, loaded with 5 wt% 
daptomycin (n= 4 with 4 pellets per 
replication). Concentrations were 
measured by high pressure liquid 
chromatography.  
Turbidity assays performed on eluates 
obtained from elution study (n= 4 with 4 
pellets per replication). Eluates 
containing daptomycin were evaluated 
for inhibitory antibiotic levels against S. 
aureus.  
Degradation tests performed with three 
CaSO4 pellet groups loaded both with 
and without 5 wt% daptomycin (n= 4 
with 4 pellets per replication). Weights of 
pellets were measured and percentage of 
original pellet remaining calculated.  
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The two types of CaSO4 used in our study were Osteoset (Wright Medical 
Technology, Arlington, TN), a sterile surgical grade, CaSO4 α-hemihydrate from 
naturally sourced United States Pharmacopeia (USP) grade gypsum, and Stimulan 
(Biocomposites, Wilmington, NC), a high-purity, completely synthetic sterile CaSO4α-
hemihydrate. The naturally sourced and synthetic CaSO4 pellets were both cast with 4.75 
g of CaSO4, with and without 5 wt%, 0.25 g, of daptomycin (Cubist Pharmaceuticals Inc, 
Lexington, MA; Lot MCB2007). The 5 wt% was previously determined using prior 
research on naturally sourced CaSO4 pellets [6,7]. Throughout our study, we used aseptic 
techniques in the fabrication of the pellets. The synthetic CaSO4 pellets were made with 
and without 2.5 mL of sterilized 3% K2SO4 solution, whereas the naturally sourced 
CaSO4 pellets were only made with 2.5 mL of 3% K2SO4 solution.  Previous research has 
determined that a concentration of 3% K2SO4 is necessary for the naturally sourced 
CaSO4 pellets because the pellets will not retain their shape without the catalyst [6]. The 
3% K2SO4 solution was substituted with 1.7 mL of sterile phosphate-buffered saline for 
the synthetic CaSO4 pellets with 0% K2SO4. We carried out all experiments in four 
replications (n = 4). Pellets were cast using 3-mm OSTEOSET® Resorbable Mini-Bead 
Kits (Wright Medical Technology; Catalog 8400-0511; Lot LB04-0028-27) and 
following the mixing method used by Wright Medical Technology described in previous 
research [6,7]. 
We performed the elution statically with four sets of each pellet variation 
distributed into four steam autoclaved 20-mL glass scintillation vials. The elution was 
conducted without stirring to maintain the structure of the pellets.  We loaded 4 mL of 
phosphate-buffered saline (PBS) into each vial and placed them in an oven at 37° C. The 
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eluates were mixed and 1-mL samples were taken at Days 1, 2, 4, 6, 8, and 10. The 
elution studies were stopped at 10 days because the antibiotic levels were below the 
HPLC detection limit. After each day’s eluate sample was collected, we replaced the 
remaining liquid with a fresh 4 mL PBS and the vials were returned to the 37° C oven. 
Eluate samples were immediately frozen in a Fisher Scientific Isotemp freezer at -20° C.   
To measure the initial daptomycin concentration loaded in the pellets, samples 
were made of each pellet variation were constructed and crushed before placing them into 
a PBS solution. The drug content of the pellets was measured before the elution because 
previous CaSO4 and daptomycin pellets had some daptomycin loss from initial loading.  
The percent daptomycin content loaded into the pellets was compared with the percent 
daptomycin released from the elution.  
To determine the eluate’s antibiotic concentration, we performed high-pressure 
liquid chromatography (HPLC) testing according to previously used methods [7]. The 
Varian (Palo Alto, CA) HPLC system was comprised of a ProStar 240 Solvent Delivery, 
ProStar 410 Autosampler, and ProStar 325 UV-Vis Detector modules. We performed 
module control and data processing using Varian’s Gala ie Chromatography Data 
System (Version 1.8.508.1). The mobile phase consisted of a HPLC-grade acetonitrile 
and water (62:38, v/v) solution including 4 mM ammonium dihydrogen phosphate 
brought to a pH of 3.25 using glacial acetic acid. Separation was accomplished using a 
Varian Microsorb-MV C8 column, 150-mm length and 4.6-mm inner diameter, with a 
flow rate of 1 mL/min. Daptomycin was detected at 232 nm with a retention time of 13.8 




We determined the CaSO4 pellets’ degradation by a common weight-based 
experiment 
1-3
. Initially, the weights of clean 20-mL glass scintillation vials were 
established and then the weight of each vial with four pellets of an individual variation 
was measured. We loaded 4 mL of PBS into each vial and stored them at 37° C. At 1-, 2-, 
4-, 6-, 8-, and 10-day time points, the PBS was removed and the pellets were allowed to 
dry at 7 ° C until a constant vial and pellet weight was obtained. After each time point’s 
sample was collected, we placed 4 mL PBS into the vials and they were returned to 37° C 
storage. The degradation was determined by the percent of pellets remaining at each time 
point calculated using the following relationship: 
Percent remaining (%) = (vial and pellets at × hours weight – vial weight)(mg)/(vial and 
initial pellets weight - vial weight)(mg) × 100 
We determined antibiotic activity against S. aureus (Cowan I strain obtained from 
Dr David Hasty, University of Tennessee Health Science Center) by using antibiotic 
elution samples in a turbidity assay. In this experiment, solution clarity after sufficient 
bacterial incubation with antibiotic eluates indicated bacterial inhibition resulting from 
antibiotic activity. As instructed by the protocol provided by the manufacturer, we 
supplemented BBL™ Mueller Hinton II Broth (Becton, Dickinson and Co, Sparks, MD; 
Lot 0071612) with 25 µg/mL Ca
2+
 in order to achieve a total Ca
2+
 concentration of 50 
µg/mL. Two hundred microliters of daptomycin eluates were added to the inoculum 
containing 1.75 mL Mueller Hinton II Broth + Ca
2+
 and 50 µL S. aureus in 5-mL 
polystyrene test tubes. The experimental setup created a 1:10 dilution of all eluates. 
Experimental groups, blanks containing neither S. aureus nor eluate samples, and positive 
controls containing S. aureus without antibiotic eluates were mixed and incubated at 37° 
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C. After approximately 20 hours of incubation at 37° C, we vortexed the tubes and the 
absorbance at 530 nm was recorded.  
All data are presented as mean ± SD and met the assumptions of a parametic test.  
We determined differences in percent degradation and daptomycin concentration between 
the pellets made from two different types of CaSO4 and the pellets made with and 
without K2SO4 using repeated measures analysis of variance and Tukey’s post hoc 
analysis using 2007 Microsoft Office Excel (Microsoft Inc, Redmond, WA) and 2004 
SigmaStat (San Jose, CA).  Differences in degradation were also analyzed with Kaplan-
Meier survival analysis with log rank, where 10% of the original pellet remaining was 
classified as failure of the pellets.  When only 10% of the original pellet remains, the 
antibiotic concentration in the pellets is typically too low and the pellets are too small to 
accurately measure.    
Results   
The degradation studies indicated differences between the sourced and synthetic 
CaSO4 pellets with 3% K2SO4 without daptomycin at Days 2 (p = 0.002), 4, 6, and 8      
(p < 0.001), as seen in Figure 2. However, Kaplan Meier analysis with log rank revealed 
no overall differences between all three CaSO4 groups without daptomycin (p = 0.368).  
When 5 wt% daptomycin was incorporated into the pellets (Figure 3), differences were 
seen between the sourced CaSO4 pellets and the synthetic CaSO4 with 0% K2SO4 at Days 








Figure 2. The graph shows the degradation results of the naturally sourced and synthetic 
CaSO4 pellets with 0% daptomycin present.  There were differences in average 
degradation of naturally sourced and synthetic CaSO4 pellets with 3% K2SO4 and 
naturally sourced and synthetic CaSO4 pellets with 0% K2SO4 at Days 2, 4, 6, and 8.  
Differences were observed between the synthetic CaSO4 pellets with 3% and 0% K2SO4 
at Days 4, 6, and 8.  Degradation is reported in wt% of original pellet remaining ± SD 
with n = 4 (
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Sourced CaSO4  pellets, 3% K2SO4, 0% daptomycin 
Synthetic CaSO4 pellets, 3% K2SO4, 0% daptomycin 
Synthetic CaSO4 pellets, 0% K2SO4, 0% daptomycin 
p = 0.001 
* * 





p = 0.002 





Figure 3. The graph shows the degradation results of the naturally sourced and synthetic 
CaSO4 pellets with 5% daptomycin present.  We observed differences in average 
degradation of naturally sourced and synthetic CaSO4 pellets with 0% K2SO4 and 
synthetic CaSO4 pellets with 3% and 0% K2SO4 at Days 1-10. Degradation is given in 
wt% of original pellet remaining ± SD with n = 4 (
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Using Kaplan Meier analysis with log rank, overall differences were seen between 
the sourced and synthetic CaSO4 pellets with 0% K2SO4 (p < 0.001) and between the 
synthetic CaSO4 pellets with 3% and 0% K2SO4 (p <0.001).  However, no differences 
were seen between the degradation of the sourced and the synthetic CaSO4 pellets with 

































Sourced CaSO4 pellets, 3% K2SO4, 5% daptomycin 
Synthesized CaSO4 pellets, 3% K2SO4, 5% daptomycin 














We observed differences in the elution profile of the sourced CaSO4 pellets and 
the synthetic CaSO4 pellets with 3% K2SO4 at Day 1 (p < 0.001) and Day 2 (p = 0.002) 
(Figure 4). The sourced CaSO4 pellets released the highest amount of daptomycin on Day 
1 and correspondingly had the highest amount of cumulative daptomycin eluted (Figure 
5), but the synthetic CaSO4 pellets with 3% K2SO4 released the largest amount of 









Figure 4. The graph shows the elution results from the naturally sourced and synthetic 
CaSO4 pellets with 5% daptomycin loaded, with mass and concentration of daptomycin 
released on the primary and secondary y axes, respectively. We found differences in the 
average mass and concentration of daptomycin released in the eluates between the 
naturally sourced and synthetic CaSO4 pellets with 3% and 0% K2SO4 at Days 1 and 2.  
Differences are shown in average mass and concentration of daptomycin released in the 
eluates between the synthetic CaSO4 pellets with 3% and 0% K2SO4 at Day 2. Mass and 
concentration are given in micrograms and micrograms per milliliter, respectively, of 
daptomycin released per pellet ± SD with n = 4 (
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Synthetic CaSO4 pellets with 0% K2SO4 
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Figure 5. The graph shows the elution results in the cumulative release form from the 
naturally sourced and synthetic CaSO4 pellets, with and without 3% K2SO4, with 5% 
daptomycin loaded.   Mass is given in micrograms of daptomycin released per pellet ± 




For evaluation of mass balance in these studies, the average percent daptomycin 
loaded and released from the three types of pellets was measured.  The average percent of 
daptomycin for the sourced CaSO4 pellets was highest at loading, at 85.1%, but the 
percent daptomycin released was highest in the synthetic CaSO4 pellets with 3% K2SO4 
at 48.8% (Table 1). The average percent daptomycin was lowest, both loaded and 















































Elution Time (days) 
Sourced CaSO4 pellets, 3% K2SO4, 5% daptomycin 
Synthesized CaSO4 pellets, 3% K2SO4, 5% daptomycin 




Table 1. Average percent daptomycin loaded in pellets and released in elution testing 
Pellet Type % Daptomycin Loaded % Daptomycin Released 
Sourced CaSO4 Pellets with 
3% K2SO4 
85.1 42.8 
Synthesized CaSO4 Pellets 
with 3% K2SO4 
81.8 48.8 
Synthesized CaSO4 Pellets 
with 0% K2SO4 
45.8 39.3 





The presence or absence of K2SO4 created differences in the degradation and the 
elution in the synthetic CaSO4 pellets. The synthetic CaSO4 pellets with 0% K2SO4 and 5 
wt% daptomycin degraded much more quickly than both types of pellets with 3% K2SO4, 
and as previously mentioned, differences were seen in degradation between the synthetic 
CaSO4 pellets with 0% K2SO4 and the other pellets using ANOVA and Kaplan Meier 
analysis. Differences were seen in the elution (Fig 4) between the synthetic CaSO4 pellets 
with 0% K2SO4 and  3% K2SO4 at Day 2 (p < 0.001) and the naturally sourced CaSO4 
pellets with 3% K2SO4 at Day 1 (p < 0.001) and Day 2 (p = 0.002).   
The eluates of the sourced CaSO4 pellets with 3% K2SO4 and 5 wt% daptomycin 
demonstrated sufficient activity against S. aureus with no bacterial growth at Days 1, 4, 
and 6 (Table 2). Eluates from synthesized CaSO4 pellets with 0% K2SO4 were only active 
against S. aureus at Days 1 and 2; however, the eluates from the synthesized CaSO4 







Table 2. The average activity for 5% loaded daptomycin (1:10 dilution) 
against of Staphylococcus aureus  
 Time points (days) 
Pellet Type 1 2 4 6 8 10 
Sourced CaSO4 Pellets with 3% K2SO4 - + - - + + 
Synthesized CaSO4 Pellets with 3% K2SO4 - - - - - + 
Synthesized CaSO4 Pellets with 0% K2SO4 - - + + + + 





The treatment of osteomyelitis is becoming complicated by the increased 
emergence of antibiotic-resistant bacteria and increases the need for local drug delivery 
over systemic delivery. The purpose of our study was to evaluate parameters of a local 
CaSO4 drug delivery system, including (1a) to determine if the pellet degradation and 
(1b) daptomycin elution profile is different for two different commercially available 
forms of CaSO4; (2) to examine if the presence of a catalyst, K2SO4, affects the 
degradation and antibiotic elution profile of the CaSO4 pellets; and (3) to verify the 
daptomycin released from both types of CaSO4 pellets is active against S. aureus, a 
bacterium commonly associated with osteomyelitis.  
Our study is limited by several factors.  First, a common limitation of most in 
vitro research is the difficulty of translating in vitro studies to in vivo studies [16]. 
Release characteristics in an in vivo environment, especially associated with a wound, are 
different than antibiotic release characteristics in vitro, in which a set volume of eluate 
and PBS is exchanged at certain intervals [16].  This study is not meant to serve as a 
surgical wound model itself, but as a supplement to in vivo studies.  Additionally, 
although we are testing four pellets at one time, elution, degradation, and activity 
properties of these pellets may be completely different in vivo in larger pellet quantities. 
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Second, we tested activity of the antibiotic to planktonic S. aureus and did not test 
inhibitory activity to bacteria within biofilms, which can be more resistant to antibiotic 
therapy and typically require additional antibiotic levels required for inhibition of 
planktonic bacteria [23].  Third, we used only one antibiotic. Increasing the number of 
evaluated antibiotics could predict if the CaSO4 type or presence of K2SO4 impacts drug 
elution and pellet degradation in different ways.  Fourth, both elution and degradation are 
dependent on numerous factors, including physical and chemical properties of materials, 
elution volumes with and without fluid exchange, and antibiotic interactions and thus we 
cannot predict elution and degradation performance across all potential applications.  
Both elution and degradation studies only provide details about the release and 
degradation characteristics of the local delivery vehicle itself, and do not account for 
affects from a local wound and the interactions between the delivery system, fluid, and 
drug.  
Our preliminary data indicate differences in degradation and elution between both 
forms of CaSO4 pellets, naturally sourced and synthetic, that could affect the clinical 
selection of a local delivery system.  As with previously researched sourced CaSO4 
pellets, all pellets exhibited a bolus release of antibiotics on Day 1 [21,26].  However,  
the total percent release of daptomycin from the naturally sourced CaSO4  pellets was 
higher and the concentration of daptomycin released on Day 1 was lower than previously 
reported (Table 3) [6,7].  The initial daptomycin released from the naturally sourced and 
synthetic calcium sulfate pellets is closer to initial antibiotics eluted from PMMA beads 
(Table 3) [24-26]. An explanation for the higher total release of the antibiotic could be 
the result of faster elution to measurement activities in comparison to previous studies. 
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Extended elution and storage could impact stability of daptomycin in solution.  The lower 
initial daptomycin concentration could be explained by the larger size of the previously 
researched CaSO4 pellets [21,26].  Although the synthetic CaSO4 pellets also exhibited a 
bolus release, more daptomycin was eluted on Day 2 compared with the naturally sourced 
CaSO4 pellets, which could demonstrate a slower antibiotic release. 
The difference in daptomycin release could be partially explained by the 
degradation differences between the types of pellets. The synthetic CaSO4 pellets with 
3% K2SO4 and 5% daptomycin demonstrated the slowest degradation, as compared to the 
other two types of pellets. Although the naturally sourced CaSO4 pellets had a faster 
degradation than the synthetic CaSO4 pellets with 3% K2SO4, the degradation of the 
naturally sourced CaSO4 pellets in our study was slower than previously reported [7]. 
However, the results could have been different because distilled water was used for the 
degradation solution instead of PBS in the previous research [7]. The presence of 
daptomycin increased the degradation rate in all three pellet types studied, but had the 
greatest effect on the degradation of the synthetic CaSO4 pellets with 0% K2SO4.  An 
explanation for this difference in degradation that has been previously reported could be 
that when the K2SO4 is absent, the daptomycin prevents the setting reaction of the CaSO4, 









Table 3. Comparisons of present study with  previous research on CaSO4 and PMMA 
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Table 3 continued. Comparisons of present study with  previous research on CaSO4 and 
PMMA 
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Although it has been previously determined that K2SO4 is necessary to form 
pellets of naturally sourced CaSO4 [7], we were able to form pellets out of synthetic 
CaSO4 without the K2SO4 catalyst.  By not incorporating K2SO4 into the pellets, the 
synthetic CaSO4 pellets degraded much more rapidly and released less daptomycin than 
the other pellets with the catalyst present.  The daptomycin released from the synthetic 
CaSO4 pellets with 0% K2SO4 is substantially less than the amount released from the 
same type of CaSO4with 0% K2SO4 that was previously reported (Table 3) [27]. 
However, the local delivery pellets used in these previous research studies were much 
larger than the pellets in this current research, 160 by 100-mm compared with 3-mm 
pellets, and Mueller Hinton broth was used as the elution vehicle instead of PBS [27]. 
Our preliminary data suggest the eluted daptomycin from both naturally sourced 
and synthetic CaSO4 pellets, with and without K2SO4, is active against S. aureus, 
inhibiting bacterial growth for varying lengths of time. While the synthetic CaSO4 pellets 
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with 3% K2SO4 demonstrated the highest activity against S. aureus, the synthetic pellets 
with 0% K2SO4 provided inhibition of S. aureus on Days 1 and 2 only, which can be 
explained by the low amount of daptomycin eluted from the pellets compared to the 
pellets with K2SO4.  The inhibitory activity of the synthetic pellets with 0% K2SO4 is 
much lower than previously reported daptomycin inhibition of S. aureus from CaSO4 and 
PMMA; however, the bacterial inhibition of the synthetic CaSO4 pellets with 3% K2SO4 
is much higher than the same reported data [12,26].  The positive growth measured on 
Day 2 for the naturally sourced CaSO4 pellets may have been caused by an unknown 
contaminant because there were similar amounts of daptomycin present in the pellets on 
Days 4 and 6.  Additionally, similar naturally sourced CaSO4 pellets were previously 
reported to inhibit S. aureus for 10 days without any contamination and inhibited S. 
aureus for 28 days with two cases of contamination [6].  
This preliminary research provides researchers and clinicians with additional 
information on the two commercially available forms of CaSO4 for a local delivery 
system for infection prevention or treatment. Our study has also shown although K2SO4 is 
not necessary for forming pellets from synthetic CaSO4, it may be helpful for decreased 
degradation, an increased daptomycin elution profile, and potentially extended activity 
against susceptible organisms. Further investigations, including preclinical in vivo studies 
and biofilm associated investigations, are needed to determine functional differences and 







1. Nandi SK, Mukherjee P, Roy S, Kundu B, De DK, Basu D. Local antibiotic 
delivery systems for the treatment of osteomyelitis- A review. Materials Science 
and Engineering C 2009;29:2478-2485. 
2. Finney MS, Crank CW, Segreti J. Use of daptomycin to treat drug-resistant 
Gram-positive bone and joint infections. Curr Med Res Opin 2005;21(12):1923-6. 
3. Hanssen AD. Local antibiotic delivery vehicles in the treatment of 
musculoskeletal infection. Clin Orthop Relat Res 2005(437):91-6. 
4. Enoch D, Bygott JM, Daly M, Kara JA. Daptomycin. J Infect 2007;55:205-213. 
5. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmocodynamics 
of daptomycin in a murine thigh model of Staphylococcus aureus infection. 
Antimicrobi Agents Chemother 2001;45:845-851. 
6. Webb ND, McCanless JD, Courtney HS, Bumgardner JD, Haggard WO. 
Daptomycin Eluted From Calcium Sulfate Appears Effective Against 
Staphyloccus. Clin Orthop Relat Res 2008;466:1383-1387. 
7. Richelsoph KC, Webb ND, Haggard WO. Elution Behavior of Daptomycin-
loaded Calcium Sulfate Pellets. Clinical Orthopaedics and Related Research 
2007;461:68-73. 
8. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance 
following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a 
daptomycin-naive patient-a review of the literature. Eur J Clin Microbiol Infect 
Dis 2010. 
9. Peltier L. The use of plaster of Paris to fill large defects in bone. Am J Surg 
1959;97:11-15. 
10. Thomas DB, Brooks DE, Bice TG, DeJong ES, Lonergan KT, Wenke JC. 
Tobramycin-impregnated calcium sulfate prevents infection in contaminated 
wounds. Clin Orthop Relat Res 2005;441:366-71. 
11. Jackson SR, Richelsoph KC, Courtney HS, Wenke JC, Branstetter JG, 
Bumgardner JD, Haggard WO. Preliminary In Vitro Evaluation of an Adjunctive 
Therapy for Extremity Wound Infection Reduction: Rapidly Resorbing Local 
Antibiotic Delivery. Journal of Orthopaedic Research 2008;7:903-908. 
12. Dacquet V, Varlet A, Tandogain R, Tahon M, Fournier L, Jehl F, Monteil H, 
Bascoulergue G. Antibiotic-impregnanted plaster of Paris beads-trials with 
teicoplanin. Clin Orthop Relat Res 1992;282:241-249. 
146 
 
13. Heijink A, Yaszemksi M, Patel R, Rouse M, Lewallen D, Hanssen A. Local 
antibiotic delivery with osteoset, DBx, and collagraft. Clin Orthop Relat 
Res 2006;451:29-33. 
14. Mackey D, Varlet A, Debeaumont D. Antibiotic loaded plaster of Paris pellets: an 
in vitro study of a possible method of local antibiotic therapy in bone infection. 
Clin Orthop Relat Res 1982;167:263-268. 
15. Diefenbeck M, Muckley T, Hofmann GO. Prophylaxis and treatment of implant-
related infections by local application of antibiotics. Injury 2006;37:S95-S104. 
16. McLaren AC. Alternative materials to acrylic bone cement for delivery of depot 
antibiotics in orthopaedic infections. Clin Orthop Relat Res 2004(427):101-6. 
17. Turner T, Urban R, Hall D, Chye P, Segreti J, Gitelis S. Local and systemic levels 
of tobramycin delivered from calcium sulfate bone graft substitute pellets. Clin 
Orthop Relat Res 2005;437:97-104. 
18. McKee M, Wild L, Schemitsch E, Waddell J. The use of an antibiotic-
impregnated, osteoconductive, bioabsorbable bone substitute in the treatment of 
infected long bone defects: early results of a prospective trial. J Orthop 
Trauma 2002;16(9):622-627. 
19. Branstetter J, Jackson S, Haggard W, Richelsoph K, Wenke J. Locally-
administered antibiotics in wounds in a limb. J Bone Joint Surg 
Br 2009;91(8):1106-1109. 
20. Gitelis S, Virkus W, Anderson D, Piasecki P, Yao TK. Functional outcomes of 
bone graft substitutes for benign bone tumors. Orthopedics 2004;27(1 
Suppl):s141-4. 
21. Cai Z-Y, Yang D-A, Zhang N, Ji C-G, Zhu L, Zhang T. Poly(propylene 
fumarate)/(calcium sulphate/B-tricalcium phosphate) composites: Preparation, 
characterization and in vitro degradation. Acta Biomaterialia 2009;5:628-635. 
22. Tomihata K, Ikada Y. In vitro and in vivo degradation of films of chitin and its 
deacetylated derivatives. Biomaterials 1997;18(7):567-75. 
23. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. 
Microbial biofilms. Annu Rev Microbiol 1995;49:711-45. 
24. McLaren AC, McLaren SG, Smeltzer M. Xylitol and glycine fillers increase 
permeability of PMMA to enhance elution of daptomycin. Clin Orthop Relat Res 
2006;451:25-8. 
25. Lewis G, Brooks JL, Courtney HS, Li Y, Haggard WO. An Approach for 
determining antibiotic loading for a physician-directed antibiotic-loaded PMMA 
bone cement formulation. Clin Orthop Relat Res 2010;468(8):2092-100. 
147 
 
26. Lewis G, Janna S. Estimation of the optimum loading of an antibiotic powder in 
an acrylic bone cement: gentamicin sulfate in SmartSet HV. Acta Orthop 
2006;77(4):622-7. 
27. Kanellakopoulou K, Panagopoulos P, Giannitsioti E, Tsaganos T, Carrer D-P, 
Efstathopoulos N, Giamerellos-Bourboulis E. In Vitro Evaluation of Daptomycin 
by a Synthetic Crystallic Semihydrate Form of Calcium Sulfate, Stimulan. 







A DAPTOMYCIN-XYLITOL-LOADED POLYMETHYLMETHACRYLATE 
BONE CEMENT HOW MUCH XYLITOL SHOULD BE USED? 
Introduction 
A recurring challenge with total joint arthroplasty (TJA) is periprosthetic joint 
infection (PJI) [13, 39, 49]. The prevalence of this phenomenon is variable, ranging from 
0.3% to 9% for primary cases [11, 48] and from 2% to 40% for revision cases [24, 49]. 
The ramifications are serious for the patient (in most cases, revision is necessary using, 
for example, the two-stage method [38]) and treatment costs are high (for example, in 
2009, in the United States, the mean total charge for revision of an infected THA was 
approximately USD 94,000 [21]). Thus, there have been many efforts to reduce the 
likelihood of PJI [13, 24] and improve treatment options [38, 45].  
One approach to improving treatment is to use an antibiotic-loaded 
polymethylmethacrylate (PMMA) bone cement (ALABC) in which the cement powder is 
blended with a novel antibiotic [15, 31]. Novel antibiotics are considered those with 
potential to have rapid and effective bactericidal activity against pathogens, such as 
methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, that have 
become resistant to many of the common antibiotics used in current approved 
commercially available ALABC brands or orthopaedic surgeon-prepared/directed 
formulations (such as gentamicin, tobramycin, and vancomycin [13, 39, 45]). Although 
there is a growing number of these novel antibiotics (eg, dalbavancin, daptomycin, 
telavancin, and tigecycline) [4, 8, 10, 12, 15, 19, 31, 42, 45], only a few, such as 
daptomycin and telavancin, have been used in PJI treatment [15, 31]. 
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Several studies have reported the in vitro properties of either low-dose 
daptomycin-loaded PMMA bone cement (low-dose is defined as  1 g daptomycin per 40 
g cement powder [13]) [5, 14, 26] or a higher-dose variant ( 2 g)  [5, 14, 26, 41]. These 
reports show the daptomycin release profile in phosphate-buffered saline (PBS) solution, 
at 37° C, is characterized by a burst followed by a period of slow decrease [5, 14, 26].  At 
relatively low amounts (up to 7.5% of the mass of the dry cement powder-daptomycin 
mixture), the daptomycin  e erts a marginal influence on the cement’s fatigue limit, 
tensile strength, yield strength, compressive strength, and compressive modulus 
(compared to the value for a cement that did not contain the antibiotic) [14, 26, 41], but 
with a higher amount of daptomycin (11 wt/wt%), there is an appreciable drop in the 
cement’s fatigue limit [26]. There is a sizeable literature on methods to improve the 
release profile of antibiotics from ALABC cylinders, including incorporation of a 
particulate filler (such as lactose, mesoporous silica nanoparticles, or xylitol) in the 
cement powder [9, 37, 43] and subjection of cured cement specimens to continuous or 
intermittent watt-level low-frequency ultrasound [3]. However, none of these reported 
methods have been evaluated for daptomycin-loaded PMMA bone cement. Also, in the 
case of an ALABC loaded with a poragen, the question as to the appropriate poragen 
amount has not been fully investigated.  
We therefore asked:  What is an appropriate amount of xylitol to be used in a 
daptomycin-xylitol-loaded PMMA bone cement? 
Materials and Methods 
The study design comprised three parts as seen in Figure 1. (1) We prepared four 
groups of cement, one not loaded with the xylitol and three having different xylitol 
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masses, namely, 0.7, 1.4, and 2.7 g; (2) For each of these four groups, we determined the 
following cement properties: fracture toughness, fatigue limit, daptomycin release rate, 
coefficient of diffusion for outflow of daptomycin (Ddapt), an index of activity of the 
daptomycin eluate against S aureus, polymerization rate at 37° C, coefficient of diffusion 
for intake of 1X PBS solution, and radiopacity (see Figure 1 for numbers of specimens or 
replicates used for each type of testing). These determined properties are of clinical 
relevance [17, 25, 29, 35, 41, 43, 44]. (3) We used an optimization method to assess an 
appropriate xylitol amount.  
The materials used were a commercially available brand of PMMA bone cement 
(Orthoset
® 
1; Wright Medical Technology, Inc, Arlington, TN, USA), daptomycin 
(Cubicin
®
; Cubist Pharmaceuticals, Lexington, MA, USA), and xylitol (XyloSweet
®
; 
XLEAR, Orem, UT, USA). The daptomycin amount used (1.36 g/40 g dry cement 
powder) was determined, from our previous work [26], based on the fatigue life, rate of 
release of daptomycin, and activity of the released daptomycin against S aureus of 
daptomycin-loaded Othoset
® 
1 cement. The xylitol amounts (X) of the cements in the 
four study groups were 0, 1.66, 3.27, and 6.13 wt/wt% of the total dry cement powder 
mixture mass. In a separate study, we used a volumetric displacement method in a liquid 
in which the powder was not soluble to determine the densities of the dry cement powder, 
daptomycin, and xylitol to be 1.25, 1.20, and 1.50 g cm
-3
, respectively. Thus, the 
corresponding xylitol amounts were 0, 1.39, 2.74, and 5.16 vol/vol% of the total dry 







Figure 1. A flowchart shows the study design. The key features of the eight cement property characterization tests conducted are 
shown: fracture toughness (Y1), fatigue limit (Y2), daptomycin elution rate (Y3), diffusion coefficient for daptomycin egress (Y4), 
inhibition index (Y5), polymerization rate, at 37° C (Y6), diffusion coefficient for PBS intake (Y7), and normalized radiopacity (Y8). 




Before the preparation of the cement groups, the daptomycin was stored at 4° ± 1° 
C, while the xylitol and the cement powder and liquid monomer were stored in ambient 
laboratory conditions (temperature and relative humidity of 21° ± 1° C and 57% ± 2%, 
respectively). A commercially available cement powder mixer (OmoMix
®
; Tecres SpA, 
Verona, Italy) was used to mix the dry cement powder, daptomycin, and xylitol.  
For the fracture toughness tests, the final powder mixture and the liquid monomer of the 
cement (18.37 mL) were vacuum-mixed using a commercially available unit (MixeVac
® 
II High-Vacuum System; Stryker Instruments, Kalamazoo, MI, USA), with an evacuation 
pressure of 74 ± 1 kPa. The prepared cement dough was injected into a stainless steel 
mold whose internal configuration and dimensions were of a compact tension test 
specimen, whose dimensions conformed to those stipulated in ASTM D5045 [2]: overall 
nominal height, width, and thickness = 35.7 mm, 37.2 mm, 14. 9 mm, respectively. The 
protocols used for finishing the specimens, accepting specimens for testing, conditioning 
the accepted specimens, performing the tests, and treating the results to obtain the 
fracture toughness (KIC) of the cement were the same as those given in our previous work 
[30].   
For the fatigue tests, the prepared cement dough was injected into a four-celled 
silicone mold, with each cell having internal configuration and dimensions of a solid 
cylindrical dog bone, whose dimensions conformed to those stipulated in ASTM F2118-
03 [1]:  overall nominal diameter and length = 8.5 mm and 62 mm, respectively. 
Protocols for inspecting the fabricated specimens, selecting acceptable specimens, 
choosing the specimens to be tested from the acceptable ones, conditioning the test 
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specimens, and performing the tests were the same as those given in our previous work 
[26].  Per ASTM F2118-03, acceptable specimens are those with no surface defects in the 
gage or transition sections and no internal defects with major diameter of larger than 1 
mm in the gage section.  The acceptable specimens were conditioned in 1X PBS, at 37° ± 
1° C, for 7 days before the tests. During the tests, the specimen was immersed in 1X PBS, 
at 37° ± 1° C. For each cement group, the combination of applied stress (S) and number 
of specimens used were ± 20 MPa (seven specimens), ± 15 MPa (seven specimens), ± 
12.5 MPa (five specimens), and ± 10 MPa (three specimens). These stresses have been 
used in many literature studies [7, 22, 26, 47], with ± 10 MPa being of the order 
postulated to be experienced in the cement mantle in a cemented TJA [18]. The test 
results were presented in the form of S versus number of cycles to fracture, Nf (as before 
[26], run-out was defined as no fracture after 1.557 million loading cycles). The method 
used for estimating the fatigue limit of the cement was the same as that used in our 
previous work [26].  
For each cement group, 75% to 89% of the fabricated specimens were found 
acceptable for fatigue testing but not all were used. From among those not used, three 
were selected at random for the daptomycin release tests. These elution tests were 
performed using the protocols in our previous study [26]. The amount of daptomycin 
released was measured in 10 mL 1X PBS solution, at 37° ± 1° C, at eight time points (t) 
of 1, 2, 5, 7, 10, 14, 21, and 28 days, with complete PBS refreshment at each time point. 
The release results were compiled as current amount of daptomycin released (W) versus t 
and cumulative amount (M) versus t. A commercially available software package 
(MATLAB
®
 R2011b; The MathWorks, Natick, MA, USA) was used to obtain the best-fit 
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relationship between W and t. The daptomycin release rate was then computed as the 
derivative of this W-versus-t relationship calculated at the value of t midway between the 
burst release point and the point at which the W-versus-t curve began to flatten.  
The release of daptomycin from a test specimen was approximated using the expression 
for release of a drug from a specimen possessing aspects of both a long cylinder and a 
thin disc [40]. With the aid of a scientific calculator (TI-89 Titanium; Texas Instruments, 
Inc, Dallas, TX, USA), the M-versus-t results and the aforementioned expression were 
used to compute Ddapt.
 
 After the daptomycin release tests were completed, eluates at each of the eight 
time points were tested for an index of antimicrobial activity against S aureus, as 
described previously [26]. Thus, 200 µL of eluates were added to 1.75 mL Mueller 
Hinton II broth supplemented with 25 µg CaCl2 per mL followed by the addition of an 
inoculum of S aureus (~10
4
 colony-forming units [CFUs]) and an overnight incubation at 
37° C. Growth was determined by measuring the optical density (OD) of the solutions, at  
530 nm, using an ultraviolet spectrophotometer (GENESYS™ 20; Thermo Scientific, 
West Palm Beach, FL, USA). The inhibition index (I) was computed as before [26]. 
The differential scanning calorimetry work was performed at a heating rate of 15 K 
minute
-1
 (DuPont 910; Instrument Specialists, Inc, Spring Grove, IL, USA). The 
protocols used and the steps employed in treating the results to obtain the cement 
polymerization rate at 37° C (k′) were as described in our previous work [30].  
 The PBS intake test involved measuring the mass gain of a circular cross-
sectioned cement disc specimen cut from the end of an acceptable fatigue test specimen 
(nominal diameter and thickness of 8.50 mm and 3.00 mm, respectively) immersed in 15 
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mL 1X PBS solution at 37° ± 1° C. Measurement continued until there was no observable 
increase in mass gain. Details of all the steps involved in using the mass gain versus time 
in PBS results to compute the PBS diffusion coefficient (DPBS) were given in our 
previous work [30]. 
 The experimental protocols followed for the determination of the radiopacity (R) 
of the cement were the same as presented in our previous work [28]. However, in the 
present work, R was calculated as the ratio of the linear attenuation coefficient (μ) for the 
cement (slope of the linear regression plot of the logarithm of OD of cement disc versus 
cement disc thickness) to μ for Al (slope of the linear regression plot of OD of Al step-
wedge versus Al step-wedge thickness) and expressed as equivalent Al% [36]. The 
normalized radiopacity (R) was computed as the ratio of R to the mass fraction of the 
radiopacifier in the cement powder (9.1 wt/wt% BaSO4 for each cement group).   
The optimization method used to assess the appropriate xylitol loading comprised 
seven steps: (1) for each of the eight cement properties, obtain the best-fit relationship 
between the determined values and X; this relationship is called an “objective function”; 
(2) for each of the cement properties, find the highest and lowest value, as given in 
previous literature; (3) for each cement property, calculate the its fractional objective 
function at a given value of X (within the range 0 - 6.13 wt/wt%) as follows: (value of the 
objective function at X – lowest literature value of property) divided by (highest literature 
value of property – lowest literature value of property); (4) for a property that should be 
as high as possible (for example, fatigue limit), calculate the quantity, (fractional 
objective function)
2
 at the X value . Call this quantity Y1. Alternatively, for each 





 at the X level Call this quantity Y2; (5) repeat steps (3) 
and (4) for all the properties and hence calculate the master modified fractional objective 
function (MMFOF) as equal to (sum of all the values of Y2)-(sum of all the values of 
Y1); (6) repeat steps (3) – (5) at other values of X (within the range 0 – 6.13 wt/wt%); (7) 
determine the appropriate value of X as that at which the maximum value of MMFOF, 
when plotted against X, occurs. Thus, this appropriate value is the one that gives the best 
tradeoff among the cement properties. The calculations in step (1) and those in steps (3) – 
(7) were carried with the aid of  commercially available software packages (TableCurve 





Microsoft Corp, Redmond, WA, USA), respectively. 
Results  
The results of the daptomycin release profile, the activity of the released 
daptomycin against S aureus, fatigue lives, and the other cement properties are presented 






















Figure 2A–B. Graphs shows the daptomycin release profiles in (A) current amount and 
(B) cumulative amount. Study sets were no xylitol (XYL-00), 0.7 wt/wt% xylitol (XYL-
07), 1.4 wt/wt% xylitol (XYL-14), and 2.7 wt/wt% xylitol (XYL-27). The daptomycin 











































































































*Values are expressed as mean ± SD; 
† 
values are expressed as mean, with 95% CIs in 
parentheses; 
‡ 
values are expressed as mean only; 
§ 
MR = mass ratio of the radiopacifier 
in the cement powder (9.1 wt/wt% BaSO4); KIC = fracture toughenss; Ddapt = coefficient 
of diffusion for outflow of Daptomycin; k’ = cement polymerization rate at 37°C; DPBS = 
coefficient of diffusion for intake of 1X phosphate-buffered saline solution; R’ = 
normalized radiopacity; XYL-00 = no xylitol; XYL-07 = 0.7 wt/wt% xylitol; XYL-14 = 






Figure 3. A graph summarizes the fatigue test results. At stresses of the order experienced 
in the cement mantle in a cemented TJA (10 MPa), xylitol did not adversely affect fatigue 
life. Study sets were no xylitol (XYL-00), 0.7 wt/wt% xylitol (XYL-07), 1.4 wt/wt% 
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Table 2. Summary of activity test results 






Elution time (days) 
1 2 5 7 10 14 21 28 
XYL-00 - - - - - + + + 62.5 
XYL-07 - - - - - - - - 100 
XYL-14 - - - - - - -/+
‡ 
- 95.8 
XYL-27 - - - - - - - - 100 
* + = growth of S. aureus (inhibition index = 0); - = inhibition of S. aureus (inhibition 
index = 100%); 
† 
for a cement, index = (sum of inhibition indexes/total number of test 
specimens (= 24); 
‡
of the three samples tested, two inhibited and one allowed growth of 
S. aureus; XYL-00 = no xylitol; XYL-07 = 0.7 wt/wt% xylitol; XYL-14 = 1.4 wt/wt% 





Using these results, the objective functions (which are given in Table 3), and the 
optimization method presented, we determined the appropriate xylitol amount to be 4.45 
wt/wt% (equivalent to final dry powder mixture composition of 1.93 g xylitol, 1.36 g 













Table 3.  Summary of the objective functions (that is, best-fit relationships between each 
of the properties determined and the xylitol loading (X)) 
Cement property Best-fit relationship Adjusted R
2a
 







Fatigue limit (Y2) Y2 = 9.378 + 0.5603 * e
-X
 0.0799 
Daptomycin elution rate 
(Y3) 





Diffusion coefficient for 
daptomycin egress (Y4)  
Y4 = 2.587 x 10
-11
 – 2.022 
x 10
-13
 * ln (X) 
0.8933 
Inhibition index (Y5)  Y5 = 96.77 * X
0.01578
  0.9575 
Polymerization rate, at 37 
o
C (Y6) 





Diffusion coefficient for 
PBS intake (Y7)   
Y7 = 4.036 x 10
-12



















In TJAs, it is common practice to use either a commercially available brand or an 
orthopaedic surgeon-prepared/directed formulation of an ALABC as a prophylaxis agent 
against PJI [13, 39, 49]. There are many reports of substantial decrease in susceptibility 
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of the pathogens involved in PJI (such as methicillin-resistant S aureus) to the antibiotic 
incorporated in the cement powder (usually, gentamicin, tobramycin, or vancomycin) 
[45]. This decrease in susceptibility provides opportunity to develop novel antibiotics. 
Among novel antibiotics, there are reports of the effectiveness of daptomycin and 
telavancin against these pathogens [15, 31]. Literature reports on daptomycin-loaded 
cement cylinders show the daptomycin release rate is low [5, 14, 26]. When a poragen 
was added to the cement powder of an ALABC, antibiotic release rate from cylindrical 
specimens increased, but there are limited data on the impact on other cement properties 
[37]. The question as to what should be an appropriate poragen amount in an ALABC 
that contains a poragen has not been posed. In this study, we determined the appropriate 
amount of xylitol to be used in a daptomycin-xylitol-loaded PMMA bone cement.  
We recognize several limitations of our study. First, although there are reports 
indicating xylitol-containing dental products may be useful in preventing or reducing the 
progression of dental caries [32]), the question as to the safety of xylitol as a constituent 
of an ALABC is an open one. However, there are reports of the beneficial effects of 
dietary xylitol against weakening of bone in aged animal models [33]. Thus, a xylitol-
loaded ALABC may be viable for use in cemented TJAs. Second, we used one cement 
brand, one antibiotic, and one brand of xylitol. Given the large numbers of cement brands 
and antibiotics available, the present approach is justified from the perspective of study 
time and cost. Third, the conditions under which the daptomycin release tests were 
conducted are different in a number of respects, notably fluid dynamics and sink details, 
from the in vivo medium in which a TJA is located [6, 23]. However, these experimental 
conditions reportedly produce vancomycin elution levels that are highly correlated with 
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those obtained from the hip of an animal model [50]. Fourth, we used a generalized 
measure of the activity of the released daptomycin against S aureus, rather than a specific 
one, such as the number of bacteria on a cement specimen (CFUs/surface area of the 
specimen).  However, the former method was used in each of the other literature studies 
of daptomycin release from ALABC cylinders [5, 14, 26]; thus, we can compare present 
trends to those in these reports. We note two caveats regarding the appropriate xylitol 
loading we determined: (1) Even though a large and diverse array of cement properties 
was determined, there are other important ones that were not. One such property is 
resistance of a cement specimen to the formation of biofilm of a given pathogen 
implicated in PJI on its surface, a phenomenon that may result in a substantial reduction 
of the susceptibility of the pathogens to daptomycin [46]. Other undetermined properties 
are working time, which gives insight into the time window between packing the cement 
dough in the bone bed and placement of the prosthesis in that bed [20]; residual monomer 
content, which provides an indication of the potential for phenomena such as chemical 
necrosis of periprosthetic tissues [16]; and fatigue crack propagation rate in PBS, at  
37° C, which may be related to the in situ life of a TJA [34]. (2) Weighting factors for the 
determined cement properties were not used; for example, considering the clinical 
application, in a head-to-head comparison between daptomycin release rate and fatigue 
limit, the former may be given a higher weighting factor. An investigation of the 
sensitivity of the assessed appropriate xylitol loading to the number of cement properties 
determined and the calculation of weighting factors for the cement properties determined 
are outside the confines of the present study. None of the above-mentioned limitations 
and caveats jeopardizes the assessed appropriate xylitol amount. However, these issues 
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should be taken into account if the present appropriate xylitol amount result is to be used 
in the clinical setting.   
In a related study, Nugent et al. [37] investigated the influence of xylitol amount 
on the properties of ALABC cylindrical specimens and found antibiotic release increased 
progressively and compressive strength of the cement decreased, with increase in xylitol 
amount. However, Nugent et al. [37] used a medium-viscosity cement [20], the antibiotic 
tobramycin, and xylitol amounts from1 g to 16 g of xylitol per 40 g of cement powder; 
hand-mixed the final powder mixture with the cement liquid monomer; and did not assess 
an appropriate xylitol amount. In contrast, we used a high-viscosity cement brand [20], 
daptomycin, and xylitol amounts from 0.7 g to 2.7 g of xylitol per 40 g of cement 
powder; vacuum-mixed the final powder mixture with the cement liquid monomer; and 
assessed an appropriate xylitol amount. Two other relevant studies were by Lewis et al. 
[26, 27] on the computation of the appropriate amount of the antibiotic in an ALABC. 
Two methodologies were used in one study [27], each involving changes of each of the 
properties determined with antibiotic dose. The methodology used in the other study [26] 
was the same as that used in the present work, but many more cement properties were 
determined in the present study (eight versus three). Thus, there are no literature studies 
comparable to the present investigation. 
In conclusion, we found an appropriate xylitol amount for a daptomycin-xylitol-
loaded PMMA bone cement was 4.46 wt/wt% (equivalent to 1.93 g xylitol mixed with 
1.36 g daptomycin and 40 g cement powder).  We recognize that this assessed amount is 
based on an analysis of a limited number of in vitro cement properties, including some 
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properties, such as the local minimum inhibitory concentration of the eluted daptomycin, 
that require confirmation from in vivo studies. 
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